

CAPITAL UNIVERSITY OF SCIENCE AND  
TECHNOLOGY, ISLAMABAD



Identification of Therapeutic  
Targets Against *Streptococcus*  
*gordonii* by Subtractive Genomic  
Analysis

by

Sadaf Kiani

A thesis submitted in partial fulfillment for the  
degree of Master of Science

in the

Faculty of Health and Life Sciences

Department of Bioinformatics and Biosciences

2020

Copyright © 2020 by Sadaf Kiani

All rights reserved. No part of this thesis may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, by any information storage and retrieval system without the prior written permission of the author.

I dedicate this thesis to my parents and my teachers.



## CERTIFICATE OF APPROVAL

### Identification of Therapeutic Targets Against *Streptococcus gordonii* by Subtractive Genomic Analysis

by

Sadaf Kiani

(MBS183014)

### THESIS EXAMINING COMMITTEE

| S. No. | Examiner          | Name                       | Organization    |
|--------|-------------------|----------------------------|-----------------|
| (a)    | External Examiner | Dr. Mazhar Qayyum          | PMASAAU, RWP    |
| (b)    | Internal Examiner | Dr. Shoukat Iqbal Malik    | CUST, Islamabad |
| (c)    | Supervisor        | Dr. Syeda Marriam Bakhtiar | CUST, Islamabad |

---

Dr. Syeda Marriam Bakhtiar

Thesis Supervisor

September, 2020

---

Dr. Sahar Fazal

Head

Dept. of Biosciences & Bioinformatics

September, 2020

---

Dr. Muhammad Abdul Qadir

Dean

Faculty of Health & Life Sciences

September, 2020

## *Author's Declaration*

I, **Sadaf Kiani** hereby state that my MS thesis titled “**Identification of Therapeutic Targets Against *Streptococcus gordonii* by Subtractive Genomic Analysis**” is my own work and has not been submitted previously by me for taking any degree from Capital University of Science and Technology, Islamabad or anywhere else in the country/abroad.

At any time if my statement is found to be incorrect even after my graduation, the University has the right to withdraw my MS Degree.

**(Sadaf Kiani)**

Registration No: MBS183014

## *Plagiarism Undertaking*

I solemnly declare that research work presented in this thesis titled “**Identification of Therapeutic Targets Against *Streptococcus gordonii* by Subtractive Genomic Analysis**” is solely my research work with no significant contribution from any other person. Small contribution/help wherever taken has been dully acknowledged and that complete thesis has been written by me.

I understand the zero tolerance policy of the HEC and Capital University of Science and Technology towards plagiarism. Therefore, I as an author of the above titled thesis declare that no portion of my thesis has been plagiarized and any material used as reference is properly referred/cited.

I undertake that if I am found guilty of any formal plagiarism in the above titled thesis even after award of MS Degree, the University reserves the right to withdraw/revoke my MS degree and that HEC and the University have the right to publish my name on the HEC/University website on which names of students are placed who submitted plagiarized work.

**(Sadaf Kiani)**

Registration No: MBS183014

## *Acknowledgements*

In the name of **Allah**, the Most Gracious and the Most Merciful Alhamdulillah, all praises to **Allah** for giving me strength and for His blessings in completing my MS thesis. First, I would like to express my sincere gratitude to Capital University of Science and Technology (CUST) Islamabad for providing me an opportunity to do MS Biosciences and achieving my goal to pursue higher studies. I would like to start with a special appreciation that goes to my Supervisor, **Dr. Syeda Marriam Bakhtiar**, for her constant support, encouragement and guidance throughout this thesis. Her door was always open whenever I needed help, she always guided me as a mentor. Then I would like to pay my special thanks to my Co-Supervisor, Assistant Professor, Syed Babar Jamal Bacha, National University of Medical Science, Islamabad for his constant support and motivation throughout the process of this thesis. I would like to thanks to my teachers Dr. Sahar Fazal, Dr. Shaukat Iqbal, Dr. Erum Dilshad, and Dr. Arshia Amin. Special thanks to my friends and colleagues (Nosheen Afzal Qureshi) for supporting me throughout this time. Finally, I express my gratitude to my parents (Shahmir Khan, Nasim Akhtar), Husband (Sardar Saddam Jahangir khan) and siblings for providing me with unfailing support and continuous encouragement throughout my years of study and through the process of researching and writing this thesis.

**(Sadaf Kiani)**

Registration No: MBS183014

---

## Abstract

*Streptococcus gordonii* belongs to viridans group streptococci, it is Gram-positive cocci. *Streptococcus gordonii*, are primarily involved in development of biofilms on tooth surfaces also known as dental plaque can result in development of infectious endocarditis i.e. inflammation of inner lining of heart. As treatment of this disease is very expensive and different bacteria has shown resistance against various commonly used antibiotics it is now important to find the novel therapeutic targets and drugs to cure and treat this disease. In this study we predict modelome of 11 strains of *Streptococcus gordonii* by using MHOLine workflow. 1,255 core proteins were identified by using pan genomic approach, later subtractive proteomics was used to extract set of 20 essential proteins for bacteria. Considering human as host, 15 of these proteins (Glutamine-fructose-6-phosphate aminotransferase, UDP-3-O-acylglucosamine N-acyltransferase, Ribonuclease P protein component, tRNA N6-adenosine threonylcarbamoyltransferase, Pseudouridine synthase, Bifunctional protein, AMP nucleosidase, Probable DNA-directed RNA polymerase subunit delta, ATP-dependent DNA helicase, Peptidase S24-like protein, TetR family transcriptional regulator, Chromosomal replication initiator protein, UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase, HTH-type transcriptional regulator, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase) were considered as essential and non-host homologs, and have been subjected to virtual screening using ZINC library. The selected ligand molecules indicated positive interactions. Comprehensive development of novel drugs and vaccine of *Streptococcus gordonii* putative proteins is shown from which some have already been reported and validated in other species.

**Keywords:** *Streptococcus gordonii*, Infectious endocarditis, Pan-genomics, Subtractive proteomics



# Contents

|  |             |
|--|-------------|
| <b>Author's Declaration</b>  | <b>iv</b>   |
| <b>Plagiarism Undertaking</b>  | <b>v</b>    |
| <b>Acknowledgements</b>  | <b>vi</b>   |
| <b>Abstract</b>  | <b>vii</b>  |
| <b>List of Figures</b>   | <b>xi</b>   |
| <b>List of Tables</b>  | <b>xiii</b> |
| <b>Abbreviations</b>   | <b>xv</b>   |
| <b>1 Introduction</b>  | <b>1</b>    |
| 1.1 Background . . . . .   | 1           |
| 1.2 <i>Streptococcus gordonii</i> in Infective<br>Endocarditis . . . . . | 3           |
| 1.3 Therapeutic Target Identification . . . . .                          | 5           |
| 1.4 Subtractive Genomics . . . . .                                       | 7           |
| 1.5 Aims and Objectives . . . . .  | 8           |
| 1.6 Objectives . . . . .   | 9           |
| <b>2 Literature Review</b>   | <b>10</b>   |
| 2.1 <i>Streptococcus gordonii</i> . . . . .                              | 11          |
| 2.1.1 Significance . . . . .   | 11          |
| 2.1.2 Genome Structure . . . . .   | 12          |
| 2.1.3 Structure of Cell and Metabolism . . . . .                         | 13          |
| 2.1.4 Ecology . . . . .  | 13          |
| 2.1.5 Pathology . . . . .  | 14          |
| 2.2 Infective Endocarditis . . . . .                                     | 16          |
| 2.3 Prevalence of Infective Endocarditis in<br>Pakistan . . . . .        | 17          |
| 2.4 Pan Genome Analysis . . . . .  | 18          |
| 2.5 Subtractive Genomic Analysis . . . . .                               | 20          |

---

|           |   |           |
|-----------|---|-----------|
| 2.6       | Drug Target Prioritization . . . . .                                  | 20        |
| 2.7       | Catalytic Pocket Detection and Molecular<br>Docking . . . . .         | 22        |
| 2.7.1     | Retrieval of Ligands . . . . .  | 22        |
| 2.7.2     | Protein Preparation . . . . .   | 22        |
| 2.7.3     | Molecular Docking . . . . .   | 23        |
| <b>3</b>  | <b>Material and Methods</b>   | <b>24</b> |
| 3.1       | Genome Selection . . . . .  | 24        |
| 3.2       | Identification of Core Genomes . . . . .                              | 24        |
| 3.3       | Identification of Essential Genes . . . . .                           | 25        |
| 3.4       | Identification of Non-Homologous and<br>Homologous Protein . . . . .  | 25        |
| 3.4.1     | Drug Target Prioritization . . . . .                                  | 26        |
| 3.4.2     | Catalytic Pocket Detection . . . . .                                  | 26        |
| 3.4.3     | Molecular Docking . . . . .   | 26        |
| <b>4</b>  | <b>Result and Analysis</b>  | <b>28</b> |
| 4.1       | Core Genome Identification of <i>Streptococcus gordonii</i> . . . . . | 28        |
| 4.1.1     | Genome Selection . . . . .  | 28        |
| 4.1.2     | Core Genome Identification using Pan-genome<br>Approach . . . . .     | 29        |
| 4.1.3     | Subtractive Genome Analysis from Core Genome . . . . .                | 29        |
| 4.1.4     | Non-homologous Proteins Identification . . . . .                      | 30        |
| 4.2       | Essential Genes Identification . . . . .                              | 30        |
| 4.3       | Drug Prioritization and Protein-Ligand<br>Interactions . . . . .      | 32        |
| 4.3.1     | Drug Prioritization . . . . .   | 32        |
| 4.3.1.1   | Molecular Weight . . . . .  | 33        |
| 4.3.1.2   | Subcellular Localization . . . . .                                    | 33        |
| 4.3.1.3   | Virulence of Target Proteins . . . . .                                | 33        |
| 4.3.1.4   | Molecular and Biological Functions . . . . .                          | 34        |
| 4.3.1.5   | Pathway Analysis . . . . .  | 34        |
| 4.3.2     | Protein-Ligand Interaction . . . . .                                  | 34        |
| 4.3.2.1   | Catalytic Pocket Detection . . . . .                                  | 34        |
| 4.3.3     | Molecular Docking . . . . .   | 39        |
| 4.3.3.1   | Ligands Selection . . . . .   | 39        |
| 4.3.3.2   | 3D Structure Prediction . . . . .                                     | 39        |
| 4.3.3.3   | Validation of 3D Structures . . . . .                                 | 40        |
| 4.3.3.4   | Docking . . . . .   | 41        |
| 4.3.3.4.1 | AMP Nucleosidase (PGN_1002) . . . . .                                 | 42        |
| 4.3.3.4.2 | Bifunctional Protein (GlmU) . . . . .                                 | 43        |
| 4.3.3.4.3 | Chromosomal Replication Initiator Pro-<br>tein (DnaA) . . . . .       | 44        |

---

|            |   |           |
|------------|---|-----------|
| 4.3.3.4.4  | UDP-3-O-acylglucosamine N-acyltransferase (lpxD) . . . . .                            | 46        |
| 4.3.3.4.5  | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate Ligase (murE) . . . . . | 47        |
| 4.3.3.4.6  | UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine Ligase (murF) . . . . .            | 49        |
| 4.3.3.4.7  | HTH-type Transcriptional Regulator (PrtR)   | 50        |
| 4.3.3.4.8  | Probable DNA-directed RNA Polymerase Subunit Delta (rpoE) . . . . .                   | 52        |
| 4.3.3.4.9  | TetR Family Transcriptional Regulator (BK761_05580) . . . . .                         | 53        |
| 4.3.3.4.10 | ATP-Dependent DNA Helicase (RecQ) . . . . .   | 54        |
| 4.3.3.4.11 | Glutamine-fructose-6-phosphate Aminotransferase (glmS) . . . . .                      | 56        |
| 4.3.3.4.12 | Ribonuclease P Protein Component (rnpA)   | 58        |
| 4.3.3.4.13 | tRNA N6-adenosine Threonylcarbamoyl Transferase (tsaD) . . . . .                      | 59        |
| 4.3.3.4.14 | Pseudouridine Synthase (MYPU_2980) . . . . .  | 59        |
| 4.3.3.4.15 | Peptidase S24-like Protein (HMPREF_1604_02797) . . . . .                              | 62        |
| <b>5</b>   | <b>Conclusions and Recommendations</b>  | <b>65</b> |
| 5.1        | Conclusions . . . . .   | 65        |
| 5.2        | Recommendations . . . . .   | 66        |
|            | <b>Bibliography</b>   | <b>67</b> |

# List of Figures

|     |   |    |
|-----|---|----|
| 1.1 | Subdivisions of Streptococcus group of Gram-Positive Bacteria . . .   | 2  |
| 1.2 | Morphology of <i>Streptococcus gordonii</i> [10]. . . . .   | 3  |
| 1.3 | Interactions between <i>Streptococcus gordonii</i> and Human Platelets causing Thrombus Formation [13]. . . . .   | 4  |
| 1.4 | Platelet-Streptococcus interactions in Pathogenesis of Infective Endocarditis [17]. . . . .   | 5  |
| 1.5 | Flow chat of Subtractive Genomics [50]. . . . .   | 8  |
| 2.1 | Proposed Mechanism linking Oral Infection to Cardiovascular Disease [29]. . . . .   | 12 |
| 2.2 | Ecological plaque hypothesis [34]. . . . .  | 14 |
| 2.3 | Casual Model of Dental Diseases Associated with Bacterial Endocarditis [36]. . . . .  | 15 |
| 3.1 | Methodological steps for Identification of Therapeutic Targets against <i>Streptococcus gordonii</i> . . . . .  | 27 |
| 4.1 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of AMP nucleosidase with ZINC72153423 . . . . .  | 42 |
| 4.2 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Bifurcational Protein with ZINC70503687 . . . . .   | 43 |
| 4.3 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Chromosomal replication initiator protein with ZINC83442116 . . . . .                           | 45 |
| 4.4 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-3-O-acylglucosamine N-acyltransferase proteinwith ZINC82049692 . . . . .                    | 47 |
| 4.5 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-N-acetylmuramoyl-L-alanyl-D-glutamate–2,6-diaminopimelate ligase withZINC70632524 . . . . . | 49 |
| 4.6 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-N-acetylmuramoyl-tripeptide–D-alanyl-D-alanine ligase-with ZINC71781357 . . . . .           | 49 |
| 4.7 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of HTH-type transcriptional regulator with ZINC71618824 . . . . .                                  | 51 |
| 4.8 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Probable DNA-directed RNA polymerase subunit delta with ZINC72267068 . . . . .                  | 53 |

---

|      |  |    |
|------|--|----|
| 4.9  | 3D Structure of Docking Analyses for most Druggable Protein Cavity of TetR family transcriptional regulator with ZINC83442116 . . .                | 53 |
| 4.10 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of ATP-dependent DNA helicase with ZINC76022877 . . . . .                       | 56 |
| 4.11 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Glutamine-fructose-6-phosphate aminotransferase with ZINC 71782238 . . . . . | 57 |
| 4.12 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Ribonuclease P protein component with ZINC 71781167 . . .                    | 59 |
| 4.13 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of tRNA N6-adenosine threonylcarbamoyltransferase with ZINC 70503687 . . . . .  | 60 |
| 4.14 | 3D Structure of Docking Analyses for most Druggable Protein Cavity of Pseudouridine synthase with ZINC83301304 . . . . .                           | 62 |
| 4.15 | 3D Structure of Docking Analyses for most Druggable Protein Cavity Peptidase S24-like protein with ZINC83442116 . . . . .                          | 63 |

# List of Tables

|      |   |    |
|------|---|----|
| 1.1  | Microbiology of Infectious Endocarditis [11]. . . . .   | 2  |
| 2.1  | List of Some Available Tool for Pan Genome Analysis Along with Their Functions. . . . .   | 19 |
| 2.2  | List of Databases and Tools for Subtractive Genomics Along with their Functions . . . . .   | 21 |
| 4.1  | Strains of <i>Streptococcus gordonii</i> with Information on Genome Statistics . . . . .  | 29 |
| 4.2  | List of Non-Homologous Pathogen-Essential Proteins . . . . .  | 30 |
| 4.3  | Drug and Vaccine target prioritization parameters (Gene name, Protein name, Uniprot ID, Virulence Factor) and functional annotation of 20 essential non-host homologous putative targets . . . . .      | 35 |
| 4.4  | Drug and Vaccine target prioritization parameters (Gene name, Protein name, KEGG Pathway and Molecular Weight) and functional annotation of 20 essential non-host homologous putative targets . . . . . | 36 |
| 4.5  | Drug and Vaccine target prioritization parameters (Gene name, Subcellular localization and Molecular Function) and functional annotation of 20 essential non-host homologous putative targets . . . . . | 37 |
| 4.6  | Drug and Vaccine target prioritization parameters (Gene name, and Biological Function) and functional annotation of 20 essential non-host homologous putative targets . . . . .                         | 38 |
| 4.7  | Validation Score of Models from Rampage and ERRAT . . . . .   | 40 |
| 4.8  | Compound name, MolDock Score and Interactive residues for AMP nucleosidase from MOE . . . . .   | 43 |
| 4.9  | Compound name, MolDock Score and Interactive residues for Bi-functional protein from MOE . . . . .  | 44 |
| 4.10 | Compound name, MolDock Score and Interactive residues for Chromosomal replication initiator protein from MOE . . . . .  | 45 |
| 4.11 | Compound name, MolDock Score and Interactive residues for UDP-3-O-acylglucosamine N-acyltransferase from MOE . . . . .  | 46 |
| 4.12 | Compound name, MolDock Score and Interactive residues for UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase from MOE . . . . .   | 48 |
| 4.13 | Compound name, MolDock Score and Interactive residues for UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase from MOE . . . . .   | 50 |

---

|      |   |    |
|------|---|----|
| 4.14 | Compound name, MolDock Score and Interactive residues for HTH-type transcriptional regulator from MOE . . . . .                 | 51 |
| 4.15 | Compound name, MolDock Score and Interactive residues for Probable DNA-directed RNA polymerase subunit delta from MOE . . . . . | 52 |
| 4.16 | Compound name, MolDock Score and Interactive residues for TetR family transcriptional regulator from MOE . . . . .              | 54 |
| 4.17 | Compound name, MolDock Score and Interactive residues for ATP-dependent DNA helicase from MOE . . . . .                         | 55 |
| 4.18 | Compound name, MolDock Score and Interactive residues for Glutamine-fructose-6-phosphate aminotransferase from MOE . . . . .    | 56 |
| 4.19 | Compound name, MolDock Score and Interactive residues for Ribonuclease P protein component from MOE . . . . .                   | 58 |
| 4.20 | Compound name, MolDock Score and Interactive residues for tRNA N6-adenosine threonylcarbamoyltransferase from MOE . . . . .     | 60 |
| 4.21 | Compound name, MolDock Score and Interactive residues for Pseudouridine synthase from MOE . . . . .                             | 61 |
| 4.22 | Compound name, MolDock Score and Interactive residues for Peptidase S24-like protein from MOE . . . . .                         | 64 |

# Abbreviations

|                          |  |
|--------------------------|--|
| <b>Blast</b>             | Basic Local Alignment Search Tool  |
| <b>DEG</b>               | Database of Essential Genes  |
| <b>Edgar</b>             | Efficient Database Framework for Comparative<br>Genome Analyses using BLAST Score Ratios |
| <b>Kegg</b>              | Kyoto Encyclopedia of Genes and Genomes  |
| <b>MOE</b>               | Molecular Operating Environment  |
| <b>MW</b>                | Molecular Weight   |
| <b><i>S.gordonii</i></b> | <i>Streptococcus gordonii</i>  |
| <b>Uniprot</b>           | Universal Protein Resource   |
| <b>Vfdb</b>              | Virulence factors Database   |



# Chapter 1

## Introduction

### 1.1 Background

Bacteria are commonly considered as Germ or cause of diseases in human beings, animals and plants. But on the other hand, various bacterial species are present on human skin, nasal passage and most commonly in mouth and gut, these species reside on human body for their whole lifetime and never cause diseases rather sometimes are considered quite beneficial to maintenance of health. Among these normal flora, imparting health benefits, some bacterial species referred as opportunistic pathogens can cause or mediate in onset of diseases. For example, streptococci among the normal flora of nose, mouth, upper airways and female genital tract, are pathogenic in nature but have very low virulence [1]. Streptococci is heterogeneous groups of organisms with complex taxonomy and belongs to Viridans group of Gram-positive cocci [1]. This group is categorized into six main groups, which includes the *Streptococcus mutans* group, *Streptococcus mitis* group, *Streptococcus anginosus* group, *Streptococcus salivarius* group, *Streptococcus bovis* group and *Streptococcus sanguinis* group [2, 3]. The *Streptococcus sanguinis* group is further subdivided into three groups *Streptococcus sanguinis*, *Streptococcus parasanguinis*, *Streptococcus gordonii* [3] and this subdivision is represented in figure 1.1.




FIGURE 1.1: Subdivisions of Streptococcus group of Gram-Positive Bacteria

TABLE 1.1: Microbiology of Infectious Endocarditis [11].

| Organism                         | Frequency (%) |
|----------------------------------|---------------|
| <i>Staphylococcus aureus</i>     | 31            |
| Viridans <i>Streptococcus</i>    | 17            |
| Coagulase-negative staphylococci | 11            |
| Enterococci                      | 11            |
| <i>Streptococcus bovis</i>       | 7             |
| Other streptococci               | 5             |
| Fungi                            | 2             |

*Streptococcus gordonii*, is a subdivision of *Streptococcus sanguinis*, and is a common inhabitant of mouth making biofilms on teeth. *Streptococcus gordonii* is basically a mesophilic, immotile cocci it grows in set of two or bead like chains [1] as depicted in figure 1.2. This bacterial specie got attention when it was found to cause infective endocarditis, where it was referred as that a dirty mouth can result into heart disease [4, 5], in addition to these *Streptococcus gordonii* was reported to be involved in onset of septic arthritis [6, 7] and spontaneous bacterial peritonitis [8, 9]. Although various other species are also reported to play their role in development of infective endocarditis, as summarized in Table 1.1.



FIGURE 1.2: Morphology of *Streptococcus gordonii* [10].

## 1.2 *Streptococcus gordonii* in Infective Endocarditis

*Streptococcus gordonii*, is a commensal (mutual benefit for host and bacteria) non-pathogenic bacteria among the normal flora of human oral microbiome. The specie is considered to play a significant role in initializing the formation of dental plaque or biofilm on teeth. It produces a surface where other bacteria can adhere. These dental plaques later cause dental cavities and other damages to teeth health. This bacterium can enter blood as a result of an injury or wound and then colonizes blood clotting agents such as platelet fibrin thrombi, and starts damaging endocardium and heat valves (Figure 1.3) Infective endocarditis could develop into a fatal disease, and this medical condition is often treated with antibacterial drugs [12]. The pathogenesis starts with the ability of *Streptococcus gordonii* to develop colonies very rapidly on the surfaces clean tooth. Human teeth are quite a reliable and promising site for biofilm formation as they are moist, warm, non-shedding




FIGURE 1.3: Interactions between *Streptococcus gordonii* and Human Platelets causing Thrombus Formation [13].

and mouth provides rich nutrition sources. This bacterial species itself is non damaging and just provides the adherence to other species which may be pathogenic. Although, the organism is not dangerous in the mouth area, but can cause acute endocarditis once reach blood stream as a result of trauma in oral region. Since *Streptococcus gordonii* is nonpathogenic but can adapt the pathogenicity of other secondary colonizers via mechanisms known as interspecies communication. The focus of research has been shifted to understand the mechanism of pathogenicity in opportunistic organisms such as streptococci which are a main cause of bacteremia inpatients whose immune system is compromised [14, 15]. Various strategies have been tried to control this species focusing especially on its ability to form biofilms on tooth surface and to decrease it is adhesion capabilities [16].

*Streptococcus gordonii* and *Streptococcus sanguinis* are among the initiators of biofilm formation and were also reported in bacterial spreads of infective endocarditis patients. Initially two species were considered one but later were identified as two separate species. Although these two species are considered safe but understanding the mechanism by which they can contribute to disease progression and how they could be controlled is need of time.

A fundamental interaction that causes pathogenesis of infective endocarditis is the one that bind bacteria directly to platelets (Figure 1.4). Due to *Streptococcus gordonii* Platelet binding by GspB emerges to be a main interaction in the pathogenesis of endocarditis. Endocarditis could be treated with antibiotic treatment and can cause mortality of host. There are few medication treatments for infective endocarditis but if the patient is allergic or resistant to these treatments than surgery is also recommended. Surgery is highly costly so we have to find novel therapeutic and drug targets to prevent the disease.




FIGURE 1.4: Platelet-Streptococcus interactions in Pathogenesis of Infective Endocarditis [17].

### 1.3 Therapeutic Target Identification

Advent of bioinformatics and Computational techniques such as comparative genomics, reverse vaccinology, Pan genomics and subtractive genomics have facilitated scientists to explore various genetic components and understand their significance in health and disease [18, 19]. Therapeutic target are basically nucleic acid or proteins whose function or activity can be altered by using external stimulation. Drug discovery is fundamentally laid on the exploration and consequent testing of drug candidates acting as therapeutic target. Advancement in genomics,

proteomics, and disease mechanisms has led to a develop concentration in finding novel targets and efficient exploration of existing targets. Knowledge of these targets is supportive for mechanism of action of drugs and for predicting features that helps to guide new drug design.

Methods such as subtractive and comparative microbial genomics and differential genome analysis [20] are also being apply for the identification of targets in a many human pathogens like *Mycobacterium tuberculosis* [21], *Burkholderia pseudomallei* [22], *Helicobacter pylori* [23], *Pseudomonas aeruginosa* [24], *Neisseria gonorrhoea* [25] and *Salmonella typhi* [26]. The main principle of these methods is to hit upon targeted genes/proteins that are crucial and necessary for the organism that cause disease and are non-homologous to the host [14], so that drugs targeting these “pathogen-essential non-host homologs” can be applied with little off targets in the host. Several essential proteins for pathogen might have a little homology to the proteins of host. On the other hand, these proteins may still choose as potential molecular targets for structure-based specific inhibitor development. Important dissimilarity in the active sites or in other druggable pockets may present, so that the pathogenic protein possibly will be targeted [15, 16].

The procedure to identify the direct molecular target, for instance protein or nucleic acid, of a small molecule is known as target identification. In medical pharmacology, target identification is proposed intended to find the effective target of a pharmaceutical or other xenobiotic. In the early hours drug discovery begin with preliminary steps of target identification and progress to the afterward phases of development. Target identification and classification starts with identification of the function of a potential therapeutic target (gene/protein) and its aim in the disease. Identification of the target is subsequently characterization of the molecular mechanisms deal with the target. An excellent target must be effective, secure, meet clinical and business necessities and must be ‘druggable’. Wet lab strategies of therapeutic target identification are time consuming, extensive and elaborate so to save the time we use insilico or computational approach for the identification of therapeutic target identification.

## 1.4 Subtractive Genomics

At this time the drugs used in treatment of diseases caused by pathogenic organisms demonstrate little to greater side effects in patients and there is wide distressing mount in the development of drug resistance strains.

Hence there is a requirement for identifying novel and effective drugs to fight with the diseases. A contemporary method known as “Subtractive genomics” is now extensively engaged to identify new and exact drug targets in organism that cause pathogenicity, as a footstep to recognizing new and potential drugs.

The process in which the host and the pathogen proteome are subtracted that’s assists in giving information for a protein set that is essential to pathogen but are not present in the host. Subtractive genomics plays a significant role in identification of potential drug targets. These targets are the proteins which are considered necessary for the organisms to survive [2]. Subtractive genome study rely on cataloging the essential proteins for a pathogen as unique in order to make possible particular drug designing (Figure 1.5).

Subtractive genomics method useful in 3 types of cases: Multi-Drug resistant pathogenic organism, Pathogenic organisms with No effective medications available, Pathogenic organism with no virulence factor identified.

This study is designed to use in-silico approaches to find the genomic information of *Streptococcus gordonii* with its proteomics to identify potent drug targets. Proteomes of 11 complete genomes which were already present were comparing using core genome approach.

Core genome includes genes present in all strains of that specie then essential proteins of organism are filtered out from the core genome. Then subtractive genomic approach is use in which all essential proteins are further check for non-homologous to the human host. The putative targets that will identified might be used to design vaccines and propose novel drugs that can bind to the proposed target protein [27].




FIGURE 1.5: Flow chat of Subtractive Genomics [50].

## 1.5 Aims and Objectives

*Streptococcus gordonii* causes dental plaque and infective endocarditis which is disease of inner lining of heart. For many years this disease is being treated with antibodies but recent research on this disease have shown antibiotic resistance against the strains of *Streptococcus gordonii*. Bioinformatics, in general, contributes through prediction of therapeutic targets which ultimately reduce men efforts and cost of experimentation. So, in this study we will contribute towards drug development against endocarditis disease by predicting novel therapeutic targets and potent lead compound for inhibition of identified targets. The promising ligand molecule can be tested in experimental laboratory that can ultimately result in commercial product in future. In this study, we use an integrative insilico



method for the predictive proteome of *Streptococcus gordonii* species to correlate the information about genome with the identification of putative therapeutic targets based on their 3D structure. The proteomes predicted from the 11 strains of *Streptococcus gordonii* were modeled by using the MHOLine workflow that is proposed by Hassan et al., 2014 [26]. There is a need of alternative novel targets and potent therapeutics to prevent the onset of the disease. The aim of the study is to identify new novel and potent therapeutics targets to prevent the onset of the infective endocarditis disease by using pan genomic approach.

## 1.6 Objectives

So, the objectives of this study include:

1. To identify core genomes of all strains of *Streptococcus gordonii*
2. To identify Essential proteins for bacteria using subtractive genomic.
3. To prioritize our protein targets, identification of potent lead compound using protein-ligand interaction.

## Chapter 2

### Literature Review

Many bacteria are present on human skin, in nose area and most commonly in mouth area and gut in normal condition, sometimes lives throughout the life of human being and does not cause any disease but when they get chance or interact with other bacteria can cause diseases such type of bacteria are known as opportunistic bacteria. The streptococci are pathogenic in nature but have very low virulence which is normally present in the mouth area and upper airways, and the female genital tract [1]. *Viridans streptococci* including *Streptococcus gordonii*, is primary bacteria which is the main cause of development of biofilms on surface of tooth known as dental plaque and ultimately cause infectious endocarditis. In some studies it was revealed that *Streptococcus gordonii* is vital cause of infective endocarditis in immunocompetent patients who have undergone a dental procedure. *Streptococcus gordonii* is basically a mesophilic, immotile cocci it grows in couples or bead like chains and comprises of heterogeneous groups of organisms with vary complex taxonomy [1].

Infective endocarditis is a disease of inner lining of heart. This disease is more common in man as compare to women. This disease is very prevalent in western countries as well as in Asian countries .In western countries this disease is most prevalent in elder people but in Asia it is more prevalent to young people age ranges from 34 to 40 years. This difference is mainly due to rheumatic heart disease is more common in Asian countries. In Pakistan the person who is suffering from

rheumatic heart disease is likely to have infective endocarditis. The main issue in treating the disease is the antibiotic resistance so in this study pan-genomic approach will be used to find the new and common drug targets for all strains of *Streptococcus gordonii* to overcome antibiotic resistance.

## 2.1 *Streptococcus gordonii*

*Streptococcus gordonii* belongs to group of Gram-positive bacterium integrated along with several earlier colonizers of the periodontal environment.[28] The organism, associated to oral streptococci, has an elevated resemblance for molecules in the salivary pellicle (or coating) on surface of tooth. *Streptococcus gordonii* consequently can swiftly colonize on the hygienic surface of tooth, and *Streptococcus gordonii* along with associated organisms consist of a high percentage i.e. up to 70%, of the bacterial biofilm forms on hygienic surface of tooth. Usually risk-free in mouth area, *Streptococcus gordonii* can cause acute bacterial endocarditis upon gaining admittance systemically. *Streptococcus gordonii* also forms an accessory layer for other colonizers of tooth surface and can modulate the pathogenicity of these secondary colonizers via a mechanism known as interspecies communication.

DNA Data Bank of Japan, European Nucleotide Archive and GenBank in 2016 deposit the whole genome sequence of *Streptococcus gordonii* [30].

### 2.1.1 Significance

The Streptococci belongs to group of gram positive, immoveable cocci that develop in the foam of pairs or bead like strings. Bacteria contained by the genus consist of both type's i.e. pathogenic bacteria and non-pathogenic bacteria that live in the mouth area, skin and upper respiratory tract of host i.e. human being and it contain *Streptococcus gordonii* and *Streptococcus mutans* [31]. *Streptococcus gordonii* is member of the viridans group of Streptococci that are fundamental




FIGURE 2.1: Proposed Mechanism linking Oral Infection to Cardiovascular Disease [29].

part of the human oral flora. These bacteria inhabit surface of tooth by making biofilms, also renowned as dental plaque. Ultimately dental plaque leads to periodontal infection and dental cavities both are the most widespread diseases in developed countries [32] (Figure 2.1). Mostly after the oral treatment *Streptococcus gordonii* is vital cause of bacterial endocarditis by entering the blood stream of host. *Streptococcus gordonii* colonizes platelet-fibrin thrombi that clot blood, in injured valves of the heart that's lead to damage function of the valves of heart. This disease can mainly treat by antibiotic therapy if not treated on time it might leads to death of host [12].

## 2.1.2 Genome Structure

Even though the full genome of *Streptococcus gordonii* has not so far been determined, but several appealing regions of chromosomal have been illustrated. Glucosyltransferase enzymes synthesize glucan polymers that are crucial for attachment

to the tooth. Parallel determinants to rgg have been illustrated in other associated bacteria present in mouth. Rgg-like determinants also present in other streptococci species which helps in regulation of different proteins with various functions. The data shows that rgg-like genes plays essential role as regulatory determinants and the function of rgg can be determined after the complete genomic sequencing of *Streptococcus gordonii* [36].

### 2.1.3 Structure of Cell and Metabolism

An individual oral cavity gives some degree of and unreliable source of diet for microorganisms live in the oral micro flora [33]. As an energy source oral *streptococci*, counting *Streptococcus gordonii*, depend on sugars that are produced primarily from carbohydrates. A key constituent in the human diet i.e. Fructose, can be attained by means of glucosyltransferases and from fructans through fructanases. Oral streptococci depend chiefly upon the phosphotransferase system (PTS) to transport carbohydrates via phosphorylation and translocation by means of a membrane. [33].

The extracellular matrix of mammals contains a lot of glycosaminoglycans containing recurring beta-linked disaccharide units. Beta-linked disaccharides are released when glycosaminoglycans are degraded. These beta-glucoside sugar substrates, including “cellobiose, arbutin, salicin and esculin,” are fermented by *Streptococcus gordonii* to produce energy [32]. Numerous putative regulons include these genes that encodes for enzymes which are essential for the process of metabolism.

### 2.1.4 Ecology

For the biofilm expansion the teeth of human beings provides an ideal environment as it is damp and lukewarm place [32]. Biofilm development starts with pioneer organisms that adhere to the surface of tooth in the human mouth area during dental plaque development. One of these pioneer organisms, *Streptococcus gordonii* is main bacteria which start colonization and help out the more colonization of

different organisms by building up a biofilm on which microscopic organisms may stick [32]. In a modern research it was revealed that *Streptococcus gordonii* was main organism that contains necessary genes that assist the addition of drifting *P. gingivalis* cells into the initial stages of a functioning biofilm [32]. Ecology plaque hypothesis is depicted in figure 2.2 Primarily, *Streptococcus gordonii* starts




FIGURE 2.2: Ecological plaque hypothesis [34].

colonization by means of arrangement of a monospecies biofilm. The surface of human tooth is coated by pellicle containing lipids and proteins which also include salivary agglutinin glycoprotein (Figure 2.2). In *Streptococcus gordonii* and other colonizers the receptors for salivary agglutinin glycoprotein and bind to the pellicle [32]. Cells of *Streptococcus gordonii*, bind to the tooth surface, then starts a signal transduction pathway, which is known as BrfAB, that regulates adhesive activity. The *Streptococcus gordonii* biofilm then play an important role as a binding site for adhesion of some additional pathogenic organisms such as *Porphyromonas gingivalis* and the process is known as coaggregation. In coaggregation specific bacteria become internally connected by specific attachments [32].

### 2.1.5 Pathology

Despite the fact that *Streptococcus gordonii* is main cause of dental plaque and establish the colonies of other pathogenic microorganisms on the surface of tooth, it is not legitimately pathogenic in the mouth. Alternatively, if *Streptococcus gordonii* once enters the circulatory system through oral bleeding it can colonize

injured heart valves so that cause endocarditis in humans beings [35]. On the damaged heart valves and endocardium blood platelets, cell fragments that assist the clotting of blood, attach to fibrinogen, the inner lining of heart, and then makes platelet-fibrin thrombi. These platelet-fibrin thrombi can become colonized by *Streptococcus gordonii* which cause injury to the valves of heart and function of the heart [35]. Figure 2.3 shows Casual Model of Dental Diseases associated with Bacterial Endocarditis.




FIGURE 2.3: Casual Model of Dental Diseases Associated with Bacterial Endocarditis [36].

During bleeding of oral pit more than 700 species of bacteria may enter to the circulatory system regardless of all that streptococci are the most well-known and significant reason of infective endocarditis [32]. *Streptococcus sanguis*, *Streptococcus oralis*, and *Streptococcus gordonii* are the three most promising pathogens that lead to endocarditis. It is inquiring that oral streptococci are competent in binding

to blood platelets particularly as the blood is not their normal habitation. Due to adaptation in one natural habitat during evolution it has allow *Streptococcus gordonii* and other oral streptococci to occupy an additional habitat [33].

Humans being with most probably having artificial heart valves develop bacterial endocarditis, heart disorders [12]. The chances of endocarditis will increased by dental procedure, urologic or gynecologic procedure and by use of intravenous medication. Various indications of bacterial endocarditis incorporates: Tiredness, Loss of hunger, Chilliness, Headaches, Joint inconvenience, The Treatment of this disease consists of intravenous anti-microbial treatment and occasionally antibiotics for a half a month [12].

## 2.2 Infective Endocarditis

Infective endocarditis is a disease of the endocardium. The endocardium is the coating of the inner layer of the chambers of the heart. This situation is commonly brought about bacteria that enter the circulatory system and infect the heart. Microbes might originate in the: mouth, skin, digestive organs, respiratory framework, and urinary tract. At the point when this situation is brought about by bacteria, it is also termed as bacterial endocarditis. In unusual cases, it may be brought about by the growth of fungus or other microorganisms. On time medical treatment is needed for infective endocarditis as it is a serious condition. If don't treated on time, the infection can injure your heart valves. This can cause issues like: Stroke, damage to different organs death.

People with healthy hearts mostly do not have this condition. Person with other heart problems is at elevated risk. If someone is at elevated risk for infective endocarditis, may require taking antibiotics before any medical and dental treatment. Antibiotics facilitate to stop bacteria to enter bloodstream and cause infection. The number of people affected is about 5 per 100,000 per year. Rates, still, differ from region to region throughout the world [36]. Mostly males are affected as compare to females [38]. The risk of death among those infected is about 25% [37].



But if remain untreated it is nearly universally fatal [38]. Symptoms of this disease may differ from man to man. In a few people, symptoms develop slowly, while others may develop symptoms suddenly. Consult to the physician if someone experiences any of the symptoms given below. People at elevated risk of endocarditis must take proper care.

The infection can cause changeless harm to the heart. If it is not fixed and treated on time, it may lead to death. We shall require having treatment in a hospital to prevent the infection from getting worst condition and causing complications. In the hospital, patient's fundamental symptoms will be observed. Patient will be treated with intravenous antibiotics (IV). When patient go to home, patient will have to use oral IV antibiotics for at least a month. At some stage in this time, patient must be keep visiting to physician. Proper blood tests after a regular period of time will show that the infection is going away.

If the heart valves of the patient have been damaged he may require surgery. Surgeon may suggest fixing the valve of heart or the valve of a patient may be changed by new valve that is made up of animal tissue or any artificial materials. Surgery might also be compulsory if the antibiotics do not work or if the infection is fungal. Infective endocarditis (IE) is a rare but distressing illness faced by both developing and developed countries

## **2.3 Prevalence of Infective Endocarditis in Pakistan**

Infective endocarditis is a vital cause of morbidity and mortality in Pakistan. In our country infective endocarditis occurs at early age. Many of the patients suffering from this disease have age less than 40. In 2004 Tariq et al. reported that median age of infective endocarditis was 24 years [40, 41] and in 2015 same group reported a shift in the median age which was 34 years. This gradual shift could be explained due to shift from communicable to non-communicable disease.

The non-communicable disease includes cardiovascular disease, diabetes, cancers and chronic airways diseases. Proper medical care is required in managing this disease [42]. these results are quite different from developed countries, as in developed countries the age of infective endocarditis is greater than 50 [43], in our country the infective endocarditis occurring at the low age is due to high frequency of rheumatic heart disease, multifactorial diseases and unrepaired congenital heart disease. The study have shown that male are more effected than female from infected endocarditis [44]. The ratio of infective endocarditis in men and women is 2:1 respectively [41].

The high prevalence of this disease in men is because men has more health check so they are exposed to nosocomial infections and intravenous drug usage is also very frequent in males [42]. Another reason for this was explained by Durente et al. That male majority of infective endocarditis decreases with the age and female harmones play a protective role against infective endocarditis [43].

That's why it is more common un men as compare to women. From the blood and tissue culture of infected patients the most frequently organism isolated is streptococcus group 36% in which about 14.2% are susceptible to penicillin [42]. The results show that in Pakistan the frequent group causing infective endocarditis is streptococcus group.

## 2.4 Pan Genome Analysis

The word “pan-genome” reflects the entire number of non-repetitive genes that are available in a given dataset. It incorporates: Core genome, Accessory genome ,species-specific or strain-specific genes [45].

It provides the genomic diversity present between the strains of a distinct species [46]. Here are some tools mentioned in table 2.1 that are available for pan-genome analysis. In this study EDGAR tool will be used. It is the software which sustains a fast and easy overview of transformative connections between genomes of microbes

TABLE 2.1: List of Some Available Tool for Pan Genome Analysis Along with Their Functions.

| Tool   | URL   | Function   | Ref  |
|--|---|--|------|
| EDGAR  | <a href="http://edgar.computational.bio.uni-giessen.de">edgar.computational.bio.uni-giessen.de</a>              | It performs homology analyses based on a particular cutoff that'sconsequently balanced to the query data.  | [47] |
| PGAT (Prokaryotic Genome Analysis Tool)                | <a href="http://nwrce.org/pgat">nwrce.org/pgat</a>  | It performs comparison between different strains of the same species, to anticipate genetic differences.   | [45] |
| PGAP – Pan-genome Analysis Pipeline                    | <a href="http://pgap.sf.net">http://pgap.sf.net</a>   | It could be a partitioned instrument utilized for the pan-genome examination, hereditary variety, advancement and work investigation of gene clusters.                     | [45] |
| PanGP: Quickly Analyzing Bacterial Pan-genome Profiles | <a href="http://PanGP.big.ac.cn">http://PanGP.big.ac.cn</a>   | It could be a isolated apparatus that was created to carry out pan-genome examination for large-scale strains withan extremely low time cost.                              | [45] |
| GET_HOMOLOGUES   | <a href="http://www.eead.csic.es/compbio/soft/gethoms.php">http://www.eead.csic.es/compbio/soft/gethoms.php</a> | It was created to perform pan-genome and comparative -genomic examination of bacterial strains   | [45] |
| Panseq – Pan-genome Sequence Analysis Program          | <a href="http://76.70.11.198/panseq">http://76.70.11.198/panseq</a>   | This tool provides data of the core and accessory genome based on the sequence identity and segmentation length.   | [45] |
| OrthoMCL   | <a href="http://www.cbil.upenn.edu">http://www.cbil.upenn.edu</a>   | This provides a scalable technique for constructing orthologous groups across multiple eukaryotic taxa, using a Markov Cluster algorithm to group (orthologs and paralogs. | [45] |

and makes simpler the procedure of obtaining new biological knowledge into their differential gene content, which permits simple browsing of precompiled datasets [47].

## 2.5 Subtractive Genomic Analysis

Subtractive genomics is the mechanism by which sequences between the host and the pathogen proteome are subtracted, which helps to provide data for a collection of proteins that are essential for pathogen but not present in the host [48]. Essential genes are the gene that helps an organism to survive.

Removal of these genes causes cell death which indicates that these genes perform necessary biological function [49]. Table 2.2 shows the some data Databases and Tools Used for Subtractive Genomics. In this study essential genes are identified by DEG database (<http://origin.tubic.org/deg/public/index.php>).

The next step is to identify non-homologous proteins. Non-homologous proteins are identified by using Blastp tool (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins>) which helps us to filter out those essential proteins which are not present in host (human).

## 2.6 Drug Target Prioritization

Several factors are required for the drug target prioritization. Molecular weight of essential and non-homologous targets will be identified by ProtParamtool for determining the Molecular function and biological process of target proteins Uniprot tool is used (<https://www.uniprot.org/>). For cellular localization of protein target CELLO online tool (<http://cello.life.nctu.edu.tw/>) will be used. For pathway analysis KEGG is used which will identify the role of the protein target in various cellular pathways. To check putative targets are involved in the pathogen virulence VFDB is used.

TABLE 2.2: List of Databases and Tools for Subtractive Genomics Along with their Functions

| Database/tools   | URL   | Function  | References                                      |
|--|---|---|---|
| NCBI bacterial genomes Recourse of bacterial             | <a href="http://www.ncbi.nlm.nih.gov/genomes/genlist.cgi?taxid%20Bacteria">http://www.ncbi.nlm.nih.gov/genomes/genlist.cgi?taxid 5 2&amp;type 5 0&amp;name 5 Complete%20 Bacteria</a> | Recourse of bacterial genomes   | Bernal et al. [2001]                            |
| GOLD: Genomes Swiss-port                                 | <a href="http://www.genomesonline.org/">http://www.genomesonline.org/</a><br>Proteome database <a href="http://www.expasy.org/sprot/">http://www.expasy.org/sprot/</a>                | Recourse of genome projects<br>Proteome database  | Bairoch & Apweiler [1997]                       |
| Database of Essential Genes (DEG)                        | <a href="http://origin.tubic.org/deg/public/index.php">http://origin.tubic.org/deg/public/index.php</a>   | Database of Screening of essential genes  | Zhang et al. [2004]                             |
| Kyoto Encyclopedia of Genes and Genomes                  | <a href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</a>   | Pathway comparison and subtraction  | Kyoto Encyclopedia of Genes Ogata et al. [1999] |
| Genomic Target Database (GTD)                            | <a href="http://www.iioab.webs.com/GTD.htm">www.iioab.webs.com/GTD.htm</a>  | Genomic Target Database List of bacteria targets based on subtractive genomics            | Barh et al. [2009]                              |
| Virulence Factors of Pathogenic Bacteria Database (VFDB) | <a href="http://www.mgc.ac.cn/VFs/main.htm">http://www.mgc.ac.cn/VFs/main.htm</a>   | Resource of virulence factors of various medically significant bacterial pathogens        | Chen et al. [2005]                              |
| CELLO  | <a href="http://cello.life.nctu.edu.tw/">http://cello.life.nctu.edu.tw/</a>   | Subcellular localization prediction for bacteria and eukaryotes                           | Yu et al. [2004]                                |
| PSORTb   | <a href="http://www.psort.org/psortb/">http://www.psort.org/psortb/</a>   | Subcellular localization prediction for gram-negative and gram-positive bacteria proteins | Gardy et al. [2005]                             |
| NCBI human BLAST   | <a href="http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid 5 9606">http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid 5 9606</a>                     | Subtraction of non-human homologue genes  | Altschul et al. [1990]                          |

## 2.7 Catalytic Pocket Detection and Molecular Docking

For the catalytic pocket detection DoGSiteScorer is used. This tool is automated pocket detection and analysis tool which is used for calculation of druggability of protein cavities. This tool will return the pocket residue and druggability score which ranges from 0-1. The score nearer to 1 indicates extremely druggable protein cavity. The predicted cavities are possibly bind to ligands with high affinity [53]. For molecular docking MOE tool is used. It has three main steps retrieval of ligands, protein preparation and molecular docking.

### 2.7.1 Retrieval of Ligands

The inhibitors will be retrieved by literature review. The structures of these inhibitors will be built utilizing MOE-Builder tool (Emerson Electric Co, St. Louis, MO). The related 3D structures will be displayed and partial charges will be determined utilizing MOE. The energies of all the molecules that are identified will be minimized by means of the algorithm of energy minimization. The accompanying parameters will be utilized for energy minimization; gradient: 0.05, Force Field: MMFF94X, Chiral Constraint: Current Geometry. All the minimized molecules will be saved in the (mdb) file format. In the subsequent stage, the prepared ligands will be utilized as input files for MOE-Dock [27].

### 2.7.2 Protein Preparation

The protein molecule considered in our investigation will be retrieved from Protein Data Bank. Water molecules will be dispensed and the 3D protonation of the molecule was done by mean of MOE. The energy of the protein molecule will be minimized utilizing the energy minimization algorithm of MOE tool. The accompanying parameters will be used for energy minimization; gradient: 0.05,

force field: MMFF94X+dolvation, chiral constraint: current geometry. Energy minimization will be terminated when the root mean square gradient falls below 0.05. The minimized structure will be used as the template for docking [31].

### 2.7.3 Molecular Docking

The binding of the ligands into the binding pocket of protein molecule will be calculated by MOE-Dock implemented in MOE. In the process of Molecular mostly used the default parameters. After performing docking, we will examine the best poses for hydrogen bonding/ $\pi - \pi$  interactions and root mean-square deviation (RMSD) calculation using MOE applications[30].

# Chapter 3

## Material and Methods

To identify therapeutic targets in *Streptococcus gordonii* methodology present in figure 3.1 was used the detail of each step are as follow:

### 3.1 Genome Selection

All the sequences of gene and protein of this bacterium are retrieved from NCBI (<https://www.ncbi.nlm.nih.gov/genome/>). Genome Assembly and Annotation report shows 53 strains of *Streptococcus gordonii* out of which 37 are contig, 5 are scaffold and 11 are complete. The eleven strains of *Streptococcus gordonii* are included in this study these strains have complete sequence.

### 3.2 Identification of Core Genomes

The word “pan-genome” reflects the entire number of non-repetitive genes that are available in a given dataset. The core genome are identified using EDGAR software [47]. In this, from all, one strain is selected as a reference strain which is used as a template strain and all other the strains are compared with the reference strains and then only those core genomes are selected which are common in all the



strains. The algorithm that it used was BLASTp with the standard scoring matrix BLOSUM62 and cut off value of  $E = 1 \times 10^{-5}$  [52].

### 3.3 Identification of Essential Genes

Essential genes are those genes which are vital for the species to survive or involve in growth. Subtractive genomics approach will be used to select conserved target which are essential to *Streptococcus gordonii*. The list of conserved proteins of *S. gordonii* which are retrieved from EDGAR software will be given to the database of essential genes: DEG (<http://origin.tubic.org/deg/public/index.php>).

The DEG contains tentatively approved evidence from bacteria and other organisms from currently available essential genomic elements for instance protein-coding genes and non-coding RNAs. Essential genes for a bacterium form a minimal genome, i.e. a series of functional modules with main roles in the emerging synthetic biology field. The default parameters will be selected, E-value=0.0001, bit score  $\geq 100$ , scoring matrix BLOSUM62 and identity  $\geq 25\%$  [53].

### 3.4 Identification of Non-Homologous and Homologous Protein

Subtractive genomics is the mechanism by which sequences between the host and the pathogen proteome are subtracted, which helps to provide data of proteins that are important for pathogen but not present in the host [12]. The identification of non-homologous and homologous protein will be carried out using NCBI BLASTp, default parameter are; E-value=0.0001, bit score  $\geq 100$ , scoring matrix BLOSUM62 and identity  $\geq 25\%$  [51].

Subtractive genomics plays a significant role in identification of potential drug targets. These targets are proteins which are considered necessary for the organisms to survive [2].

### 3.4.1 Drug Target Prioritization

There are numerous factors that can help in determining potential therapeutic targets such as molecular weight, molecular function, cellular localization, pathway analysis and virulence [56]. Molecular weight is determined by ProtParam tool (<http://web.expasy.org/protparam/>). Molecular functions and biological functions for every protein target is determined by Uniprot(<https://www.uniprot.org/>).

Cellular localization of pathogen is performed by CELLO (<http://cello.life.nctu.edu.tw/>). For pathway analysis the KEGG web tool (<https://www.genome.jp/kegg/>) is used which will determine the function of protein targets in various cellular pathways. To identify virulence of protein targets VFDB is used which determines the pathogenic virulence of the protein targets.

### 3.4.2 Catalytic Pocket Detection

For the catalytic pocket detection DoGSiteScorer will be used. It is automated pocket detection and analysis tool which is used for calculation of druggability of protein cavities. This tool will return the pocket residue and druggability score which ranges from 0-1. The score closer to 1 indicates highly druggable protein cavity. The cavities that are predicted possibly bind ligands with high affinity [51].

### 3.4.3 Molecular Docking

For the protein-ligand binding the MOE (Molecular Operating Environment) software is used. The binding of the ligands into the binding pocket of protein molecule is calculated by MOE-Dock implemented in MOE. Molecular docking is performed with most of the default parameters. After performing docking, we analyzed the most excellent poses for hydrogen bonding/ $\pi-\pi$  interactions and root mean-square deviation (RMSD) calculation using MOE applications [30].




FIGURE 3.1: Methodological steps for Identification of Therapeutic Targets against *Streptococcus gordonii*

# Chapter 4

## Result and Analysis

### 4.1 Core Genome Identification of *Streptococcus gordonii*

Identification of core genome is based on two steps these are genome selection and identification of core genes by using an approach i.e. pan genome approach.

#### 4.1.1 Genome Selection

The number of selected strains for this study is eleven. To get more accurate results we select only those stains which have complete genome. The proteins and genes of these complete genomes of eleven strains of *Streptococcus gordonii* were retrieved from NCBI (<https://www.ncbi.nlm.nih.gov/genome/>). Genome selection is first step for identification of core genome. Genome Assembly and annotation report provide data of 53 strains of *Streptococcus gordonii* out of which 37 are contig, 5 are scaffold and 11 are complete. Table 4.1 shows the 11 strains of *streptococcus gordonii* having complete genome and names of all selected strains, genome size in Mb ,GC content, total number of genes present in strain and total number of proteins. The above mentioned information on genome statistics plays an important role in core genome identification.

TABLE 4.1: Strains of *Streptococcus gordonii* with Information on Genome Statistics

| Sr. # | Organisms/<br>Name   | Strain                     | Genome<br>size<br>(Mb) | GC %  | Total<br>genes | Total<br>Protein |
|-------|--|----------------------------|------------------------|-------|----------------|------------------|
| 1     | <i>S.gordonii</i><br><i>str. Challis</i><br><i>substr. CH1</i> | Challis<br>substr. CH1     | 2.19666                | 40.50 | 2152           | 2014             |
| 2     | <i>S. gordonii</i>   | NCTC7865                   | 2.18761                | 40.60 | 2150           | 2004             |
| 3     | <i>S. gordonii</i>   | KCOM 1506<br>(= ChDC B679) | 2.28331                | 40.60 | 2273           | 2131             |
| 4     | <i>S. gordonii</i>   | NCTC9124                   | 2.22391                | 40.40 | 2180           | 2012             |
| 5     | <i>S. gordonii</i>   | FDAARGOS_257               | 2.22271                | 40.40 | 2206           | 2060             |
| 6     | <i>S. gordonii</i>   | NCTC7868                   | 2.19666                | 40.50 | 2149           | 2015             |
| 7     | <i>S. gordonii</i>   | FDAARGOS_683               | 2.19659                | 40.50 | 2133           | 2010             |
| 8     | <i>S. gordonii</i>   | IE35                       | 2.1901                 | 40.50 | 2144           | 2032             |
| 9     | <i>S. gordonii</i>   | NCTC10231                  | 2.18555                | 40.60 | 2132           | 1993             |
| 10    | <i>S. gordonii</i>   | NCTC3165                   | 2.1548                 | 0.50  | 2156           | 2005             |
| 11    | <i>S. gordonii</i>   | FDAARGOS_371               | 2.12131                | 40.70 | 2102           | 1963             |

#### 4.1.2 Core Genome Identification using Pan-genome Approach

EDGAR website was used to identify Pan Genomes. The EDGAR requires one strain as reference strain all other strains which were selected as complete genome from NCBI are compared with the reference strain. In this study the selected reference strain was *Challis substr. CH1* then rest of strains was compared with this reference strain. The result was in the form of table which contain the locus tag and description of genes along with the Fasta file. Total number of genes identified in pan-genome is 2,835 genes, out of these 1,255 core genes were identify. Then this data is further used for the subtractive genome analysis.

#### 4.1.3 Subtractive Genome Analysis from Core Genome

Subtractive genome analysis is a computational approach used to recognize the non-homologous proteins and these non-homologous are essential genes which are necessary for the survival of an organism.

#### 4.1.4 Non-homologous Proteins Identification

NCBI-BLASTp was used to identify the non-homologous proteins. Default parameters were used against human genome to filter out the non-homologous proteins. Core genome of all 1,255 Protein sequences was subjected to Blastp, from which 643 were non-homologous proteins. Then these non-homologous proteins were used to identify essential proteins.

## 4.2 Essential Genes Identification

Essential genes are genes that are needed necessarily for the continued existence of pathogen and help to perform all important functions of life for instance entry into host, adherence, causing disease and determination within the host. The core 643 non-host homologous proteins were given to the Database of Essential Gene (DEG) for the recognition of essential proteins, and then final set of 20 proteins was attained shown in table 4.2.

TABLE 4.2: List of Non-Homologous Pathogen-Essential Proteins

| Query_ID        | DEG ID      | Percent Identity | E_Value | Protein Name   |
|-----------------|-------------|------------------|---------|--|
| SGO_<br>RS00230 | DEG10480279 | 68.571           | 0.001   | Glutamine-fructose-<br>6-phosphate<br>aminotransferase<br>UDP-3-O- |
| SGO_<br>RS00780 | DEG10200254 | 56.41            | 0.001   | acylglucosamine-<br>N-acyltransferase                              |
| SGO_<br>RS00875 | DEG10410143 | 52.941           | 0.001   | Ribonuclease P<br>protein component                                |
| SGO_<br>RS01020 | DEG10070130 | 52.381           | 0.001   | YSIRK_signal<br>domain<br>protein                                  |

---

| Query_ID        | DEG ID      | Percent Identity | E_Value | Protein Name   |
|-----------------|-------------|------------------|---------|--|
| SGO_<br>RS01040 | DEG10200056 | 52.239           | 0.001   | Peptidase C51 domain<br>-containing protein                  |
| SGO_<br>RS01090 | DEG10130190 | 50.898           | 0.001   | tRNA N6-adenosine<br>threonyl<br>carbamoyltransferase        |
| SGO_<br>RS01400 | DEG10320340 | 49.505           | 0.001   | AraC family<br>transcriptional regulator                     |
| SGO_<br>RS01590 | DEG10140111 | 47.368           | 0.001   | Pseudouridine synthase                                       |
| SGO_<br>RS01610 | DEG10430020 | 47.059           | 0.001   | Glycosyl transferase   |
| SGO_<br>RS01705 | DEG10120121 | 46.296           | 0.001   | Bifunctional protein GlmU                                    |
| SGO_<br>RS01715 | DEG10220213 | 45.833           | 0.001   | AMP nucleosidase   |
| SGO_<br>RS02060 | DEG10060014 | 44.828           | 0.001   | Probable DNA-<br>directed RNA<br>polymerase<br>subunit delta |
| SGO_<br>RS02090 | DEG10050245 | 44.444           | 0.001   | ATP-dependent DNA<br>helicase RecQ                           |
| SGO_<br>RS02330 | DEG10480104 | 42.424           | 0.001   | Peptidase S24-like protein                                   |
| SGO_<br>RS02440 | DEG10470298 | 41.463           | 0.001   | TetR family transcriptional<br>regulator                     |
| SGO_<br>RS02520 | DEG10480275 | 40.625           | 0.001   | Chromosomal replication<br>initiator<br>protein DnaA         |

---

| Query_ID        | DEG ID      | Percent Identity | E_Value | Protein Name   |
|-----------------|-------------|------------------|---------|--|
| SGO_<br>RS02545 | DEG10230225 | 40               | 0.001   | UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase            |
| SGO_<br>RS02885 | DEG10430422 | 37.757           | 0.001   | Peptidoglycan D, D-transpeptidase FtsI                               |
| SGO_<br>RS03190 | DEG10360030 | 37.395           | 0.001   | HTH-type transcriptional regulator PrtR                              |
| SGO_<br>RS03305 | DEG10320013 | 36.531           | 0.001   | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate—2,6-diaminopimelate ligase |

### 4.3 Drug Prioritization and Protein-Ligand Interactions

The study was further divide into two steps to identify the best therapeutics target. First step was drug prioritization it will provide information of target proteins about their druggability and protein-ligand interaction was determined the catalytic pockets and will perform molecular docking of target protein.

#### 4.3.1 Drug Prioritization

Several factors contribute to determine the potential therapeutic targets such as molecular weight, molecular function and cellular function, virulence and pathway analysis.



#### 4.3.1.1 Molecular Weight

For drug targeting the determination of molecular weight (MW) is one of the important and basic step. Best molecular weight for targets are less than 100 kilo Dalton (kDa) the target who have MW less than 100 are considered as best Therapeutic targets [43]. Molecular weight of proteins was calculated by online tool Protparam.

This tool calculates the molecular weight in g/mol after converting the MW of proteins into kDa, molecular weight of all proteins was less than 100kDa. Molecular weight of all proteins is shown in table 4.4.

#### 4.3.1.2 Subcellular Localization

The environment where proteins work is known as subcellular localization. Subcellular localization impacts the protein work by controlling access to and accessibility of a wide range of molecular interaction partner.

The data of localization of protein normally have a vital role in defining the cellular function of hypothetical and newly discovered proteins [50]. 15 proteins were cytoplasmic, 3 were membrane proteins and 2 were extracellular and periplasmic protein out of total 20 proteins. This division of proteins is shown in table 4.5.

#### 4.3.1.3 Virulence of Target Proteins

Pathogens are responsible for causing several human diseases by invading the host immune mechanism, this is known as virulence.

When these non-homologous and essential proteins are declared as virulent, then these can be fundamental significance to reveal novel therapeutics targets.

In this study VFDB is used to find out the virulent proteins. All the targeted proteins are found to be virulent except Ribonuclease P protein component. A virulent target protein is shown in table 4.3.

#### 4.3.1.4 Molecular and Biological Functions

Biological and molecular function plays a vital role in consideration of the protein. Biological function and molecular function are different from each other. Gene ontology shows that molecular function describes activities that take place at molecular level, e.g. transport or catalysis, whereas biological process is complex and extensive process and it is accomplished by multiple molecular activities [55]. In this study uniprot web is used to find out the molecular and biological function of the proteins. Biological and molecular function of all the target proteins is shown in table 4.5 and 4.6 respectively.

#### 4.3.1.5 Pathway Analysis

Pathway analysis of the targeted proteins tells us about the function of these targets in various cellular pathways. Pathway analysis of genomic data signifies one potential track for computational inference of drug targets. KEGG database was used in this study to find out the pathways of the targeted proteins. These pathways of targeted proteins are shown in table 4.4.

### 4.3.2 Protein-Ligand Interaction

The basic step for the protein-ligand interaction is to detect the catalytic pockets of targeted proteins, this will show the binding sites of the protein for the binding to the corresponding ligand and then to perform molecular docking.

#### 4.3.2.1 Catalytic Pocket Detection

DoGSiteScorer is used to find out the catalytic pockets. For all target proteins those pockets were selected and only those were selected whose drug ability score was above than 0.6. The druggability score greater than 0.6 is considered to be good but score greater than 0.8 is preferential. The score which is nearer to 1 shows extremely druggable protein cavity.

TABLE 4.3: Drug and Vaccine target prioritization parameters (Gene name, Protein name, Uniprot ID, Virulence Factor) and functional annotation of 20 essential non-host homologous putative targets

| S.# | Gene Name            | Protein Name  | Uniprot ID     | Virulence |
|-----|----------------------|---|----------------|-----------|
|     |                      | Glutamine-fructose  |                |           |
| 1   | glmS                 | -6-phosphate<br>aminotransferase<br>[isomerizing]<br>UDP-3-O-                     | V0V2E2         | Yes       |
| 2   | lpxD                 | acylglucosamine<br>N-acyltransferase  | B8GWR3         | Yes       |
| 3   | rnpA                 | Ribonuclease P protein<br>component   | Q6NC40         | No        |
| 4   | SPRM2<br>00_0325     | YSIRK_signal<br>domain protein  | A0A5C<br>1BBB9 | Yes       |
| 5   | CC_0349              | Peptidase C51 domain<br>-containing protein                                       | Q9AB82         | Yes       |
| 6   | tsaD                 | tRNA N6-adenosine threonyl<br>carbamoyltransferase                                | Q6FCK9         | Yes       |
| 7   | gadX                 | AraC family transcriptional<br>regulator  | A0A0U<br>1ITI1 | Yes       |
| 8   | MYPU_2980            | Pseudouridine synthase  | Q98QR3         | Yes       |
| 9   | BGC29_04275          | Glycosyl transferase  | A0A1E3<br>M6M1 | Yes       |
| 10  | Glum                 | Bifunctional protein GlmU   | A0Q565         | Yes       |
| 11  | PGN_1002             | AMP nucleosidase  | B2RJH6         | Yes       |
| 12  | rpoE                 | Probable DNA-directed RNA<br>polymerase subunit delta                             | P47268         | Yes       |
| 13  | recQ                 | ATP-dependent DNA<br>helicase RecQ  | P71359         | Yes       |
| 14  | HMPREF<br>1604_02797 | Peptidase S24-like protein  | V0V7J8         | Yes       |
| 15  | BK761_05580          | TetR family transcriptional<br>regulator  | A0A243<br>DXR5 | Yes       |
| 16  | dnaA                 | Chromosomal replication<br>initiator protein DnaA                                 | Q1R4N5         | Yes       |
| 17  | murF                 | UDP-N-acetylmuramoyl-<br>tripeptide-D-alanyl-<br>D-alanine ligase                 | Q8A1L7         | Yes       |
| 18  | ftsI                 | Peptidoglycan D,D<br>-transpeptidase FtsI   | D0CCM7         | Yes       |
| 19  | prtR                 | HTH-type transcriptional<br>regulator PrtR  | Q06553         | Yes       |
| 20  | murE                 | UDP-N-acetylmuramoyl<br>-L-alanyl-4<br>D-glutamate-2,6-<br>diaminopimelate ligase | A0A0H<br>3NH87 | Yes       |

TABLE 4.4: Drug and Vaccine target prioritization parameters (Gene name, Protein name, KEGG Pathway and Molecular Weight) and functional annotation of 20 essential non-host homologous putative targets

| S.# | Gene Name        | KEGG Pathways   | Molecular Weight (g/mol) |
|-----|------------------|---|--------------------------|
| 1   | glmS             | 1.Alanine, aspartate and glutamate metabolism<br>2.Amino sugar and nucleotide sugar metabolism<br>3.Metabolic pathways<br>4.Biosynthesis of antibiotics | 66866.28                 |
| 2   | lpxD             | no hit  | 34329.93                 |
| 3   | rnpA             | no hit  | 12879.05                 |
| 4   | SPRM200_0325     | no hit  | 196144.2                 |
| 5   | CC_0349          | no hit  | 24925.36                 |
| 6   | tsaD             | no hit  | 36723.48                 |
| 7   | gadX             | no hit  | 33325.26                 |
| 8   | MYPU_2980        | no hits   | 34431.91                 |
| 9   | BGC29_04275      | no hits   | 36093.57                 |
| 10  | Glum             | 1.Amino sugar and nucleotide sugar metabolism<br>2.Metabolic pathways<br>3.Biosynthesis of antibiotics  | 49637.92                 |
| 11  | PGN_1002         | no hits   | 29031.2                  |
| 12  | rpoE             | no hits   | 17057.05                 |
| 13  | recQ             | Homologous recombination  | 70055.52                 |
| 14  | HMPREF1604_02797 | no hits   | 28164.26                 |
| 15  | BK761_05580      | no hits   | 23607.51                 |
| 16  | dnaA             | Two-component system  | 52550.81                 |
| 17  | murF             | 1.Vancomycin resistance<br>2.Peptidoglycan biosynthesis<br>3.Lysine biosynthesis<br>4.Metabolic pathways  | 47729.11                 |
| 18  | ftsI             | beta-Lactam resistance  | 64726.66                 |
| 19  | prtR             | no hits   | 28111.87                 |
| 20  | murE             | 1. biosynthesis of Peptidoglycan<br>2.Metabolic pathways<br>3.Two-component system  | 53286.67                 |

TABLE 4.5: Drug and Vaccine target prioritization parameters (Gene name, Subcellular localization and Molecular Function) and functional annotation of 20 essential non-host homologous putative targets

| S.# | Gene Name        | Subcellular localization | Molecular Function   |
|-----|------------------|--------------------------|--|
| 1   | ghmS             | Cytoplasmic              | 1. Carbohydrate derivative binding 2. glutamine-fructose-6-phosphate transaminase  |
| 2   | lpxD             | Cytoplasmic              | N-acyltransferase activity   |
| 3   | rnpA             | Cytoplasmic              | 1. ribonuclease P activity 2.tRNA binding  |
| 4   | SPRM200_0325     | cellwall                 | 1.carbohydrate binding 2.glycopeptide alpha-N-acetylgalactosaminidase activity   |
| 5   | CC_0349          | Extracellular            |  |
| 6   | tsaD             | Cytoplasmic              | 1.iron ion binding2.metalloendopeptidase activity<br>3.N(6)-L-threonylcarbamoyladeninesynthase activity  |
| 7   | gadX             | Membrane                 | 1.DNA-binding transcription factor activity 2.sequence-specific DNA binding  |
| 8   | MYPU_2980        | Cytoplasmic              | 1.lyase activity 2.pseudouridine synthase activity 3.RNA binding   |
| 9   | BGC29_04275      | Membrane                 | transferase activity   |
| 10  | Glum             | Cytoplasmic              | 1.glucosamine-1-phosphate, N-acetyltransferase activity 2.magnesium ion binding<br>3.UDP-N-acetylglucosamine diphosphorylase activity  |
| 11  | PGN_1002         | Cytoplasmic              | AMP nucleosidase activity  |
| 12  | rpoE             | Cytoplasmic              | DNA-directed 5'-3' RNA polymerase activity   |
| 13  | recQ             | Cytoplasmic              | 1.3'-5' DNA helicase activity 2.ATP binding 3.DNA binding  |
| 14  | HMPREF1604_02797 | Cytoplasmic              | DNA binding  |
| 15  | BK761_05580      | Cytoplasmic              | DNA binding  |
| 16  | dnaA             | Cytoplasmic              | 1.ATP binding 2.DNA replication origin binding   |
| 17  | murF             | Cytoplasmic              | 1.ATP binding 2.UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase activity<br>1. Penicillin binding 2.eptidoglycan glycosyltransferase activity<br>3.serine-typeD-Ala-D-Alacarboxypeptidase activity |
| 18  | ftsI             | Membrane                 | DNA binding  |
| 19  | prtR             | Cytoplasmic              | 1. ATP binding 2.magnesium ion binding   |
| 20  | murE             | Cytoplasmic              | 3.UDP-N -acetylmuramoylalanyl-D-glutamate-2,6 -diaminpeptidase activity  |

TABLE 4.6: Drug and Vaccine target prioritization parameters (Gene name, and Biological Function) and functional annotation of 20 essential non-host homologous putative targets

| S.# | Gene Name        | Biological Function   |
|-----|------------------|---|
| 1   | glmS             | 1.Carbohydrate derivative biosynthetic process 2.carbohydrate -metabolic process  |
| 2   | lpxD             | lipid A biosynthetic process  |
| 3   | rnpA             | tRNA 5' -leader removal   |
| 4   | SPRM200_0325     |   |
| 5   | CC_0349          |   |
| 6   | tsaD             | tRNA threonylcarbamoyladenosine modification  |
| 7   | gadX             | Transcription, Transcription regulation   |
| 8   | MYPU_2980        | pseudouridine synthesis   |
| 9   | BGC29_04275      |   |
| 10  | Glum             | 1.cell morphogenesis 2.cell wall organization 3.lipid A biosynthetic process<br>4.lipopolysaccharide biosynthetic process 5.peptidoglycan biosynthetic process<br>6.regulation of cell shape 7.UDP-N-acetylglucosamine biosynthetic process |
| 11  | PGN_1002         | 1.AMP salvage 2.nucleoside metabolic process  |
| 12  | rpoE             | 1.regulation of transcription, DNA-templated 2.transcription, DNA-templated   |
| 13  | recQ             | 1.DNA duplex unwinding 2.DNA recombination 3.DNA repair 4.DNA replication 5.SOS response  |
| 14  | HMPREF1604_02797 |   |
| 15  | BK761_05580      | Transcription, Transcription regulation   |
| 16  | dnaA             | 1.DNA replication initiation 2.regulation of DNA replication  |
| 17  | murF             | 1.cell cycle 2.cell division 3.cell wall organization 4.peptidoglycan biosynthetic process  |
| 18  | ftsI             | 1.cell wall organization 2.division septum assembly 3.FtsZ-dependent cytokinesis<br>4.peptidoglycan biosynthetic process 5.regulation of cell shape   |
| 19  | prtR             | 1.bacteriocin biosynthetic process 2.negative regulation of secondary metabolite biosynthetic process   |
| 20  | murE             | 1.cell cycle 2.cell division 3.cell wall organization 4.peptidoglycan biosynthetic process  |

### 4.3.3 Molecular Docking

Molecular docking has three main steps which includes: Selection of ligands, 3D structure prediction of targeted protein, Protein-ligand docking.

#### 4.3.3.1 Ligands Selection

The ligand library was prepared by compounds from ZINC database (ZINC drug-like molecules). ZINC library has 1605 molecules, with Tanimoto cutoff level of 60%. 15 top positioned compounds for all targeted proteins were evaluated for figure complementarity and hydrogen bond interactions. This provides direction to the final selection of set of compounds with polypharmacology and polypharmacy characteristics for target proteins in *Streptococcus gordonii*.

#### 4.3.3.2 3D Structure Prediction

As the structure of all these targeted proteins was not available at protein databank so the structure of these proteins was predicted by using the tool available for 3D structure prediction named SwissModel [46]. This tool is selected to find structures of targeted proteins because it is used worldwide, its performance is continuously evaluated and interface is user friendly. It has an easy access to modeling results, their visualization and its interpretation. To use this tool input all targeted protein sequences in fasta format then next step is Data Search, in this for the provided data it searches its evolutionary related protein structure against Swiss-Model Template Library (SMTL). This will use two databases on backend. One is BLAST which is quick and adequately precise. And the other is HHblits which add sensitivity to the remote homology structure [46]. The pair of proteins which have same structure and functions but lack easily detectable sequence similarity are known as remote homologs [45]. Than third step is selection of template. It shows all top ranked templates whose quality was estimated by Global Model Quality Estimate (GMQE). Those templates were selected whose

sequence similarity score was high. Final step is to build model upon the selected template it builds the 3D structure for the targeted proteins.

#### 4.3.3.3 Validation of 3D Structures

Quality of 3D structures was validated by using RAMPAGE and ERRAT tool which are online tools available. Rampage stands for RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression. Ramachandran plot was used by this tool and provide validation score for each target protein 3D structures. Score of RAMPAGE greater than 80 is considered as good score [47]. The input of this tool is .pdb file of 3D structure of targeted protein. So in this study the score of all targeted proteins are greater than 80. for more accuracy another tool ERRAT was used for validation. Quality factor greater than 37% is considered good [48]. The input of this tool is also .pdb file and quality factor for all predicted 3D structures were greater than 70 (Table 4.7).

TABLE 4.7: Validation Score of Models from Rampage and ERRAT

| S.# | Protein Name                                    | Rampage | ERRAT   |
|-----|---|---------|---------|
| 1   | Glutamine-fructose-6-phosphate aminotransferase | 95.10%  | 94.382~ |
| 2   | UDP-3-O-acylglucosamine-~N-acyltransferase      | 95.00%  | 81.7241 |
| 3   | Ribonuclease P protein component                | 94.20%  | 94.8454 |
| 4   | YSIRK_gnal domain protein                       | 96.50%  | 95.1165 |
| 5   | Peptidase C51 domain-containing protein         | 88.70%  | 82.6087 |
| 6   | tRNA N6-adenosine ~threonylcarbamoyltransferase | 94.50%  | 85.5219 |
| 7   | AraC family transcriptionalregulator            | 98.00%  | 100     |
| 8   | Pseudouridine synthase                          | 92.10%  | 85.4545 |
| 9   | Glycosyl transferase                            | 91.40%  | 88.5135 |



|    |  |        |          |
|----|--|--------|----------|
| 10 | Bifunctional protein   | 95.70% | 87.8571  |
| 11 | AMP nucleosidase   | 93.10% | 95.2174~ |
| 12 | Probable DNA-directed<br>RNA polymerase subunit delta                              | 86.70% | 81.5789  |
| 13 | ATP-dependent DNA helicase   | 95.70% | 96.2     |
| 14 | Peptidase S24-like protein   | 80.70% | 70.8995  |
| 15 | TetR family transcriptionalregulator   | 95.80% | 99.4536  |
| 16 | Chromosomal replication<br>~initiator protein                                      | 93.10% | 88.0368  |
| 17 | UDP-N-acetylmuramoyl-<br>tripeptide-D-alanyl-D-alanine ligase                      | 92.80% | 86.0577  |
| 18 | Peptidoglycan D,D-transpeptidase   | 89.50% | 82.7236  |
| 19 | HTH-type transcriptionalregulator  | 94.10% | 100      |
| 20 | UDP-N-acetylmuramoyl - L -<br>alanyl - D- glutamate-2,<br>6-diaminopimelate ligase | 96.30% | 93.3619  |

#### 4.3.3.4 Docking

MOE tool was used for the purpose of docking. Ligands were converted into .mdb file by minimizing molecular energy and by adding hydrogen having default parameters. Molecular docking was performed; the targeted proteins were opened in MOE. Than all solvent present in targeted protein i.e. ligands were deleted. In next step hydrogen was added, 3D protonation and energy minimization was done and save it in .mdb file. Than minimized structure of targeted protein was opened and docking was performed by selecting the ligands .mdb file here default parameters were used. Final step i.e. analysis was done in this step 1605 ligand of ZINC library were sort in ascending order of docking score. First 15 ligands were selected for each targeted proteins and there interaction was save as PNG. 3D figure representation for the best protein-ligand interaction of each targeted protein was drawn in chimera tool.

#### 4.3.3.4.1 AMP Nucleosidase (PGN\_1002)

AMP nucleosidase (AMN) enzyme is present in prokaryotes only, in prokaryotes it has an important role in purine nucleoside salvage and intracellular AMP level control. The activity of the protein is invigorated by ATP and smothered by phosphate. AMN is a common homohexamer, and every monomer is consisting of two domains:

- (1) Catalytic domain
- (2) Putative regulatory domain.




FIGURE 4.1: 3D Structure of Docking Analyses for most Druggable Protein Cavity of AMP nucleosidase with ZINC72153423

In general topology of the catalytic domain and a few features of the substrate binding site bear a resemblance to those of the nucleoside phosphorylases, revealing that AMN is a novel constituent of the family. It is a cytoplasmic protein which is essential for the survival of bacteria; this can be a potential drug target after wet lab research.

The compound name, MolDock score and interactive residues are shown in table 4.8 and 3D structural representation for the best protein-ligand interaction of this protein identified by MOE tool were drawn in Chimera tool as shown in figure (figure 4.1).

TABLE 4.8: Compound name, MolDock Score and Interactive residues for AMP nucleosidase from MOE

| S.No | Ligand       | Interacting residues                         | Docking score | Energy (kcal/mol) |
|------|--------------|--|---------------|-------------------|
| 1    | ZINC83246639 | Phe_229_A,Gln_223_A.                         | -13.3335      | -14.214           |
| 2    | ZINC72447036 | Phe_229_A                                    | -12.7731      | -19.571           |
| 3    | ZINC71827951 | Lys_94_A                                     | -12.6645      | -17.051           |
| 4    | ZINC72354549 | Val_225_A,Asp_208_A                          | -12.6202      | -20.049           |
| 5    | ZINC71772423 | Phe_229_A                                    | -12.6001      | -19.225           |
| 6    | ZINC78547466 | Gln_223_A,Asn_228_A,Tyr_35_A                 | -12.3686      | -14.877           |
| 7    | ZINC71784817 | Asp_208_A                                    | -12.2603      | -13.870           |
| 8    | ZINC78870135 | Asp_208_A                                    | -12.2293      | -63.451           |
| 9    | ZINC76555281 | Tyr_35_A                                     | -12.1491      | -16.163           |
| 10   | ZINC75106924 | Asn_228_A                                    | -12.0858      | -15.189           |
| 11   | ZINC80316400 | 2/Lys_94_A                                   | -11.9432      | -12.586           |
| 12   | ZINC83262599 | No hit                                       | -11.8772      | -17.083           |
| 13   | ZINC71783863 | Gln_223_A                                    | -11.8194      | -12.617           |
| 14   | ZINC82114814 | Val_225_A,Asp_222_A                          | -11.7993      | -16.761           |
| 15   | ZINC72153423 | Asp_208_A,Gln_223_A,<br>2/Asn_228_A,Phe_32_A | -11.7803      | -60.722           |

#### 4.3.3.4.2 Bifunctional Protein (GlmU)

The glmU gene plays a vital role to catalyze the development of UDP-N-acetyl glucosamine, a fundamental precursor for cell wall peptidoglycan and lipopolysaccharide biosyntheses [56]. GlmU protein is actually a bifunctional protein which moreover catalyzes acetylation of glucosamine-1-phosphate. It is essential protein




FIGURE 4.2: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Bifurcational Protein with ZINC70503687

TABLE 4.9: Compound name, MolDock Score and Interactive residues for Bi-functional protein from MOE

| S.No | Ligand       | Interacting residues | Docking score | Energy (kcal/mol) |
|------|--------------|----------------------|---------------|-------------------|
| 1    | ZINC71789643 | Lys_389_B            | -22.8298      | -29.383           |
| 2    | ZINC71404930 | Lys_389_C            | -20.9783      | -21.836           |
| 3    | ZINC71777127 | Tyr_363_C            | -19.2816      | -37.031           |
| 4    | ZINC83262599 | Lys_389_C            | -18.5302      | -26.288           |
| 5    | ZINC70503687 | Lys_389_C,Lys_357_B  | -18.1773      | -41.343           |
| 6    | ZINC82039595 | Lys_389_C            | -17.8068      | -22.246           |
| 7    | ZINC79036966 | Arg_330_C            | -17.8062      | -17.160           |
| 8    | ZINC78547526 | Lys_389_C,Arg_330_C  | -17.6660      | -27.220           |
| 9    | ZINC73736642 | Tyr_363_C            | -17.5962      | -26.138           |
| 10   | ZINC72187422 | Lys_389_C,Arg_330_C  | -17.5919      | -19.049           |
| 11   | ZINC82049692 | Asn_383_C,Lys_348_C  | -17.5387      | -20.093           |
| 12   | ZINC70632524 | Lys_357_B,Lys_389_C  | -17.5250      | -13.521           |
| 13   | ZINC71609301 | Lys_389_C            | -17.5180      | -12.168           |
| 14   | ZINC71782238 | Arg_330_C            | -17.3807      | -20.835           |
| 15   | ZINC71610591 | Lys_389_C            | -17.0571      | -12.237           |

for the survival of bacteria and drug prioritization also confirm that it could act as drug target. The compound name, MolDock score and interactive residues are shown in table 4.9 and 3D structural representation for the best protein\_ligand interaction of this protein identified by MOE tool were drawn in chimera tool as shown in figure (figure 4.2)

#### 4.3.3.4.3 Chromosomal Replication Initiator Protein (DnaA)

In all organisms the start of DNA replication is a main occasion in the cell cycle. Replication initiation takes place at specific origin sequences that are predictable and processed by an oligomeric complex of the initiator protein DnaA in bacteria. The complex consists of three subcomplexes, and spatial arrangements of those over and above their components are vital for well-organized replication initiation. It is a cytoplasmic protein which is essential for the survival of bacteria, this can be potential drug target after the wet lab research. The compound name, MolDock score and interactive residues are shown in table 4.10 and 3D structural representation for the best protein-ligand interaction of this protein identified by MOE tool were drawn in chimera tool as shown in figure (figure 4.3)




FIGURE 4.3: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Chromosomal replication initiator protein with ZINC83442116

TABLE 4.10: Compound name, MolDock Score and Interactive residues for Chromosomal replication initiator protein from MOE

| S.No | Ligand       | Interacting residues                                    | Docking score | Energy (kcal/mol) |
|------|--------------|---|---------------|-------------------|
| 1    | ZINC70503687 | Thr_435,Asp_433,<br>Thr-436,Gln_408,<br>Arg_399,Arg_407 | -11.9844      | -52.042           |
| 2    | ZINC72271115 | Arg_399   | -11.9760      | -15.097           |
| 3    | ZINC74723614 | Lys_443,Arg_407   | -11.7191      | -20.346           |
| 4    | ZINC71610591 | 2/Lys_443,Gln_408                                       | -11.5903      | -7.439            |
| 5    | ZINC83312796 | Thr_436, Arg_399,Arg_407                                | -11.1673      | -21.306           |
| 6    | ZINC71777127 | Lys_443,Arg_407,Gln_408                                 | -11.0657      | -29.789           |
| 7    | ZINC80053835 | Lys_397,Thr_436   | -10.9858      | -22.135           |
| 8    | ZINC71613886 | No hit  | -10.9660      | -8.862            |
| 9    | ZINC83442116 | Lys_443,2/Arg_407,2/Gln_408                             | -10.9359      | -12.800           |
| 10   | ZINC71778026 | Arg_432,Lys_397   | -10.8917      | -13.927           |
| 11   | ZINC71781167 | Lys_443,2/Arg_407,Gln_408                               | -10.8701      | -27.019           |
| 12   | ZINC71781091 | 2/Thr_436   | -10.8696      | -17.284           |
| 13   | ZINC72338622 | Lys_443,Arg_407   | -10.8370      | -16.870           |
| 14   | ZINC71762339 | Lys_443,Arg_407,Thr_436                                 | -10.8120      | -17.141           |
| 15   | ZINC71777128 | 2/Lys_443,Arg_407                                       | -10.7452      | -28.377           |

#### 4.3.3.4.4 UDP-3-O-acylglucosamine N-acyltransferase (IpxD)

Outer membrane of Gram-negative bacteria is mainly made up of a defensive, selectively permeable LPS.

TABLE 4.11: Compound name, MolDock Score and Interactive residues for UDP-3-O-acylglucosamine N-acyltransferase from MOE

| S.No | Ligand       | Interacting residues                              | Docking score | Energy (kcal/mol) |
|------|--------------|---|---------------|-------------------|
| 1    | ZINC71789643 | Lys_79_, Ser_99_,<br>Phe_13_, Ser_99_,<br>Lys_79_ | -14.8215      | -23.508           |
| 2    | ZINC71610591 | Arg_08_   | -13.8215      | -6.901            |
| 3    | ZINC71609301 | Lys_79_   | -13.8045      | -20.434           |
| 4    | ZINC71777127 | Arg_08_, Arg_45_,<br>Arg_63_                      | -12.9378      | -21.482           |
| 5    | ZINC82049692 | Arg_63_, His_04_,<br>Ala_09_, Gly_91_             | -12.6946      | -17.780           |
| 6    | ZINC71783040 | His_04_, Arg_63_                                  | -12.6930      | -4.519            |
| 7    | ZINC80316400 | Lys_79_, Lys_79_                                  | -12.5641      | -29.834           |
| 8    | ZINC78976572 | Ser_82_, Arg_63_                                  | -12.5188      | -15.795           |
| 9    | ZINC78701498 | Lys_79_, Lys_79_,<br>Ser_99_                      | -12.3822      | -13.645           |
| 10   | ZINC83313306 | Ser_82_, Arg_63_                                  | -12.3730      | -19.317           |
| 11   | ZINC83406748 | Asp_03_, Gly_93_,<br>Arg_63_                      | -12.2312      | -20.795           |
| 12   | ZINC72271115 | Ser_82_, Arg_63_                                  | -12.1796      | -16.614           |
| 13   | ZINC77257146 | Lys_79_, Lys_79_,<br>Ala_97_                      | -12.1678      | -23.648           |
| 14   | ZINC72291787 | Arg_63_, Glu_89_                                  | -12.1589      | -22.991           |
| 15   | ZINC69741273 | Ser_82_, Ala_90_,<br>Arg_63_                      | -12.0914      | -10.388           |

Biosynthesis of LPS depends on UDP-3-O-acyl-glucosamine N- acyltransferase (LpxD), which transfers 3-hydroxy-arachidic acid from acyl carrier protein, to the 2' amine of UDP-3-O-myristoyl glucosamine in *Chlamydia trachomatis*. It is vital protein for the continued existence of bacteria and drug prioritization also confirm that it could act as drug target. The compound name, MolDock score and interactive residues are shown in table 4.11 and 3D structural representation for the best protein-ligand interaction of this protein identified by MOE tool were drawn in chimera tool as shown in figure (figure 4.4)




FIGURE 4.4: 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-3-O-acylglucosamine N-acyltransferase protein with ZINC 82049692

#### 4.3.3.4.5 UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2, 6-diaminopimelate Ligase (murE)

This is an enzyme present in cytoplasm, which catalyzes the addition of meso-diaminopimelic acid to nucleotide originator in the biosynthesis of cell-wall peptidoglycan of bacteria. The cell wall of bacteria composed of polymeric network of murein. This polymeric protects the cell wall from surplus water in its surrounding. This protein initiates the synthesis of murein by adding mesodiaminopimelic acid to UDP-N-acetylmuramoyl-l-alanyl-d-glutamate in cytoplasm. This protein play vital role in survival of bacteria the reason is that its cell wall synthesis could acts as a putative drug target. Table 4.12 illustrates a set of 15 potential ligands

according to their MolDock score and minimized energy value from the above mentioned ZINC library.

TABLE 4.12: Compound name, MolDock Score and Interactive residues for UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase from MOE

| S.No | Ligand       | Interacting residues                | Docking score | Energy (kcal/mol) |
|------|--------------|-------------------------------------|---------------|-------------------|
|      |              | Arg_0,Leu_,Ser_,Ala_,Gln_,His_,     |               |                   |
| 1    | ZINC72233583 | Gln_1, Asn_7,<br>Thr_8,Arg_3,Ser_5  | -17.5631      | -85.785           |
| 2    | ZINC71777792 | 3/Glu_9<br>His_0,Arg_7,             | -15.7656      | -13.961           |
| 3    | ZINC71780763 | Lys_4,Asp_0,<br>His_1,Lys_0,~Tyr_8  | -15.7521      | -22.630           |
| 4    | ZINC70632524 | Asp_0,Lys_4,<br>Arg_7,Thr_8         | -15.6213      | -14.412           |
| 5    | ZINC70632388 | Lys_0,His_0,Thr_8,Thr_3             | -15.5324      | -16.037           |
| 6    | ZINC78611957 | Arg_7<br>Lys_4,Asp_0,               | -15.4265      | -13.686           |
| 7    | ZINC71618824 | His_1,Tyr_8<br>Tyr_1,3/Lys_0,       | -15.1914      | -23.003           |
| 8    | ZINC79482538 | Lys_5,2/Ser_6,His_7                 | -15.1322      | -17.551           |
| 9    | ZINC71827951 | Arg_0,Arg_3,Thr_9,<br>Asn_7,Lys_0   | -14.6894      | -14.002           |
| 10   | ZINC71777127 | 2/Arg_7,Lys_4,His_0                 | -14.6312      | -27.119           |
| 11   | ZINC71610591 | Lys_4,Arg_7                         | -14.5694      | -14.478           |
| 12   | ZINC70503687 | Lys_4,Asp_0,2/His_0,<br>Lys_0,Tyr_8 | -14.5318      | -39.500           |
| 13   | ZINC72145573 | Lys_4,Thr_5                         | -14.5214      | -21.089           |
| 14   | ZINC71404930 | Arg_7,Thr_5,Lys_4                   | -14.4313      | -21.566           |
| 15   | ZINC71609301 | Arg_7                               | -14.3715      | -8.148            |






FIGURE 4.5: 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase with ZINC70632524

#### 4.3.3.4.6 UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine Ligase (murF)

MurF is necessary to catalyze the ultimate step within the synthesis of the cytoplasmic precursor of the cell wall peptidoglycan of bacteria and is an attractive target for drug development such as antibacterial drugs. Evaluation with the complex crystal structures of MurD and its substrates, the topology of the N-terminal domain of MurF is unique, as its central and C-terminal domains exhibit similar mononucleotide and dinucleotide-binding folds, correspondingly. It is a cytoplas-




FIGURE 4.6: 3D Structure of Docking Analyses for most Druggable Protein Cavity of UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase with ZINC71781357

mic protein which is essential for the survival of bacteria, this can be potential drug target after the wetlab research. Table 4.13 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.

TABLE 4.13: Compound name, MolDock Score and Interactive residues for UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase from MOE

| S.No | Ligand       | Interacting residues            | Docking score | Energy (kcal/mol) |
|------|--------------|---------------------------------|---------------|-------------------|
| 1    | ZINC78556566 | Lys_8,Ser_8,Asn_3               | -16.6791      | -21.935           |
| 2    | ZINC72194390 | Lys_8,Thr_4                     | -13.8823      | -28.881           |
| 3    | ZINC72333100 | Asn_6,Ser_8,Lys_8               | -13.7611      | -29.626           |
| 4    | ZINC83442116 | Lys_3,Asn_4,<br>Arg-307,Thr_4   | -13.6617      | -19.529           |
| 5    | ZINC73824605 | No hit                          | -13.5822      | -21.945           |
| 6    | ZINC71951504 | Lys_3                           | -13.4810      | -16.213           |
| 7    | ZINC71789643 | Lys_3,Asn_4,Lys_8,Asp_1         | -13.4496      | -26.394           |
| 8    | ZINC75163962 | Thr_4                           | -13.3015      | -27.270           |
| 9    | ZINC71781357 | Arg-307,Thr_4,Lys_3,Asn_4,Ser_9 | -13.2128      | -20.339           |
| 10   | ZINC78547526 | No hit                          | -13.1210      | -25.325           |
| 11   | ZINC71863887 | Lys_8                           | -12.8958      | -25.034           |
| 12   | ZINC71177577 | Asn_4                           | -12.8336      | -22.438           |
| 13   | ZINC83293606 | Lys_8,Gly_2                     | -12.8308      | -29.615           |
| 14   | ZINC73825281 | Asp_1,Ser_8,Ala_2               | -12.7234      | -4.895            |
| 15   | ZINC72463312 | Asn_6,Asp_1                     | -12.4934      | -16.017           |

#### 4.3.3.4.7 HTH-type Transcriptional Regulator (PrtR)

Helix-turn-helix (HTH) is a key structural motif able to bind to DNA. Every monomer includes two  $\alpha$  helices that bind to the major groove of DNA connected by a short strand of amino acids. The HTH motif takes places in many proteins

TABLE 4.14: Compound name, MolDock Score and Interactive residues for HTH-type transcriptional regulator from MOE

| S.No | Ligand       | Interacting residues  | Docking score | Energy (kcal/mol) |
|------|--------------|-----------------------|---------------|-------------------|
| 1    | ZINC71863768 | Lys_3,Arg_15          | -14.0707      | -10.370           |
| 2    | ZINC71777127 | 2/Lys_3,Val_67,Arg_15 | -13.8433      | -29.231           |
| 3    | ZINC83442116 | Arg_15,Ser_4          | -13.3139      | -17.542           |
| 4    | ZINC83332969 | Lys_3,Arg_15          | -13.2665      | -21.484           |
| 5    | ZINC71787260 | Lys_3,2/Arg_15        | -13.2521      | -10.998           |
| 6    | ZINC71609301 | Lys_3,Arg_15          | -13.1373      | -7.915            |
| 7    | ZINC70632524 | Lys_3,Ser_4           | -12.6732      | -11.859           |
| 8    | ZINC83295231 | 2/Lys_3,Arg_15        | -12.6568      | -29.114           |
| 9    | ZINC72372215 | 2/Lys_3,Arg_15        | -12.5929      | -27.290           |
| 10   | ZINC83262599 | No hit                | -12.4528      | -28.749           |
| 11   | ZINC72343413 | 2/Arg_15              | -12.3619      | -33.209           |
| 12   | ZINC71618824 | 2/Lys_3,Arg_15,Ser_4  | -12.2688      | -33.038           |
| 13   | ZINC73630165 | Lys_3                 | -12.2672      | -18.166           |
| 14   | ZINC71785005 | Arg_15                | -12.2487      | -15.524           |
| 15   | ZINC80316400 | Lys_3,Arg_15          | -12.2115      | -25.639           |

that regulate gene expression. This will assume not to be mistaken for the helix-loop-helix motif [57]. The helix-turn-helix motif is a DNA-binding motif. It is essential protein for the survival of bacteria and drug prioritization also confirm that it could act as drug target. Table 4.14 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.




FIGURE 4.7: 3D Structure of Docking Analyses for most Druggable Protein Cavity of HTH-type transcriptional regulator with ZINC71618824

#### 4.3.3.4.8 Probable DNA-directed RNA Polymerase Subunit

##### Delta (rpoE)

TABLE 4.15: Compound name, MolDock Score and Interactive residues for Probable DNA-directed RNA polymerase subunit delta from MOE

| S.No | Ligand       | Interacting residues | Docking score | Energy (kcal/mol) |
|------|--------------|----------------------|---------------|-------------------|
| 1    | ZINC71603491 | Arg_3,Glu_0          | -12.4968      | -18.603           |
| 2    | ZINC74941352 | Glu_0                | -12.2533      | -15.459           |
| 3    | ZINC83294593 | Glu_0                | -11.6314      | -13.202           |
| 4    | ZINC82163903 | Glu_0,Glu_7          | -11.5909      | -21.346           |
| 5    | ZINC71780841 | Asp_7,Tyr_4,Tyr_3    | -11.3396      | -14.553           |
| 6    | ZINC73822846 | Asn_1,Arg_3          | -11.1254      | -10.826           |
| 7    | ZINC72267068 | Glu_0,Lys_3          | -10.8458      | -5.179            |
| 8    | ZINC71967867 | Lys_8,Glu_3          | -10.8158      | -17.461           |
| 9    | ZINC72194481 | Glu_0                | -10.4065      | -14.324           |
| 10   | ZINC71776694 | Tyr_4,Tyr_3          | -10.1654      | -15.233           |
| 11   | ZINC72232841 | No hit               | -10.0472      | -11.803           |
| 12   | ZINC83250876 | No hit               | -9.9741       | -7.017            |
| 13   | ZINC70461088 | Arg_3,Asp_9          | -9.8596       | -11.453           |
| 14   | ZINC83439122 | Tyr_3,Tyr_4          | -9.8466       | -15.506           |
| 15   | ZINC72272542 | Tyr_3                | -9.7337       | -18.518           |

The gene rpoE (RNA polymerase, extracytoplasmic E) predetermines the sigma factor sigma-24 ( $\sigma$ 24, sigma E, or RpoE), a protein in *E. coli* and many species of bacteria. Based on the bacterial species, this gene might be known as sigE. RpoE has been reported as an essential gene for exocyttoplasmic stress response. Without rpoE *E. coli* mutants are not able to grow up at elevated temperatures (i.e. > 42 °C) and illustrate growth deficiency at lower temperatures, although this might be due to compensatory mutations. In several bacterial species, for instance *Clostridium botulinum*, this sigma factor conceivably necessary for sporulation. The Hfq protein in *E. coli* transform the stress response activity of RpoE [6]. It is a cytoplasmic protein which is essential for the survival of bacteria, this can be potential drug target after the wetlab research. Table 4.15 illustrates a set of 15

potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.




FIGURE 4.8: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Probable DNA-directed RNA polymerase subunit delta with ZINC72267068

#### 4.3.3.4.9 TetR Family Transcriptional Regulator (BK761\_05580)

TetR family of regulators (TFRs) is generally correlated with antibiotic resistance and it helps to regulation of genes that encodes for the exporters of small-molecule.




FIGURE 4.9: 3D Structure of Docking Analyses for most Druggable Protein Cavity of TetR family transcriptional regulator with ZINC83442116

TABLE 4.16: Compound name, MolDock Score and Interactive residues for TetR family transcriptional regulator from MOE

| S.No | Ligand       | Interacting residues               | Docking score | Energy (kcal/mol) |
|------|--------------|------------------------------------|---------------|-------------------|
| 1    | ZINC78611957 | Lys_94                             | -14.2283      | -11.564           |
| 2    | ZINC70632388 | Lys_94,Gln_124,<br>Thr_162         | -14.1354      | -6.356            |
| 3    | ZINC72145573 | Gln_111                            | -14.0751      | -9.421            |
| 4    | ZINC78868921 | Lys_94                             | -13.8527      | -13.472           |
| 5    | ZINC70503687 | Thr_162,Asp_166                    | -13.5175      | -29.403           |
| 6    | ZINC83313306 | Lys_94,Thr_162                     | -13.4713      | -30.280           |
| 7    | ZINC83442116 | Gln_124,Leu_106,<br>Thr_162,Lys_94 | -13.2859      | -18.230           |
| 8    | ZINC82039595 | Lys_94                             | -13.1124      | -11.479           |
| 9    | ZINC71781091 | Lys_94,Thr_162                     | -13.0461      | -18.023           |
| 10   | ZINC71285802 | Glu_69                             | -12.9859      | -11.921           |
| 11   | ZINC72233583 | Lys_94                             | -12.8267      | -11.215           |
| 12   | ZINC72194390 | Lys_94,Thr_162                     | -12.8232      | -21.944           |
| 13   | ZINC71186802 | Gln_124,Lys_94,<br>Thr_162         | -12.8084      | -20.718           |
| 14   | ZINC70632524 | Lys_127,Gln_124                    | -12.8031      | -4.507            |
| 15   | ZINC71973421 | Leu_107,Lys_94,<br>Asp_166         | -12.7250      | -14.120           |

On the other hand, TFRs plays a much wider role in controlling genes involved in metabolism, production of antibiotic, quorum sensing, and numerous other features of prokaryotic physiology. It is essential protein for the survival of bacteria and drug prioritization also confirm that it could act as drug target. Table 4.16 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.

#### 4.3.3.4.10 ATP-Dependent DNA Helicase (RecQ)

The RecQ helicases plays a vital role in maintenance of chromosomes and their faults play a crucial role in many disorders and in human it cause cancer. The RecQ helicases belong to an significant family of highly conserved DNA helicases. RecQ is essential in prokaryotes for recombination of plasmid and DNA repair from Ultraviolet-light, free radicals, and alkylating agents. ATP-dependent DNA helicase protein also helps to reverse damage from replication errors.

Normally without RecQ proteins replication does not continue in eukaryotes, it also have important role in aging, silencing, recombination and DNA repair. It is a cytoplasmic protein which is essential for the survival of bacteria, this can be potential drug target after the wetlab research. The compound name, MolDock score and interactive residues are shown in table 4.17 and 3D structural representation for the best protein\_ligand interacton of this protein identified by MOE tool were drawn in chimera tool as shown in figure (figure 4.10).

TABLE 4.17: Compound name, MolDock Score and Interactive residues for ATP-dependent DNA helicase from MOE

| S.No | Ligand       | Interacting residues    | Docking score | Energy (kcal/mol) |
|------|--------------|-------------------------|---------------|-------------------|
| 1    | ZINC82087835 | Asp_188                 | -11.9702      | -40.180           |
| 2    | ZINC72463312 | Tyr_189,Asn_390,Gln_486 | -11.6775      | -6.108            |
| 3    | ZINC76022877 | Gln_193, 2/Ser_490      | -11.3723      | -14.770           |
| 4    | ZINC79493313 | Tyr_391                 | -11.3078      | -17.908           |
| 5    | ZINC71780157 | 2/Ser_490,Arg_197       | -11.2574      | -14.778           |
| 6    | ZINC77969011 | Ser_490                 | -11.2256      | -8.337            |
| 7    | ZINC72153423 | Glu_372, Tyr_391        | -11.1743      | -44.055           |
| 8    | ZINC76063543 | Tyr_189,Asn_390         | -10.8976      | -21.397           |
| 9    | ZINC71973421 | Gln_487                 | -10.8918      | -8.515            |
| 10   | ZINC71780763 | Tyr_189 ,Tyr_391        | -10.8894      | -3.922            |
| 11   | ZINC71778026 | 2/Ser_490,Gln_193       | -10.8796      | -14.642           |
| 12   | ZINC71778472 | Ser_490,Gln_193         | -10.7741      | -18.675           |
| 13   | ZINC83260916 | Asp_188,Ala_190         | -10.7485      | -20.554           |
| 14   | ZINC77291760 | Gln_193                 | -10.7443      | -23.516           |
| 15   | ZINC72272542 | Ser_490,Gln_193         | -10.7442      | -15.542           |




FIGURE 4.10: 3D Structure of Docking Analyses for most Druggable Protein Cavity of ATP-dependent DNA helicase with ZINC76022877

#### 4.3.3.4.11 Glutamine–fructose-6-phosphate Aminotransferase (glmS)

Glucosamine-6-phosphate aminotransferase (GlmS) controls ammonia from glutamine at the glutaminase site to fructose 6-phosphate at the site of synthase. In *Escherichia coli* GlmS is consists of two C-terminal synthase domains that makes the dimer interface and two N-terminal glutaminase domains at its periphery. Addition of transposon Tn7 into the *E.coli* glmS work as a transcriptional terminator [58]. It is essential protein for the survival of bacteria and drug prioritization also confirm that it could act as drug target. Table 4.18 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.

TABLE 4.18: Compound name, MolDock Score and Interactive residues for Glutamine–fructose-6-phosphate aminotransferase from MOE

| S.No | Ligand       | Interacting residues       | Docking score | Energy (kcal/mol) |
|------|--------------|----------------------------|---------------|-------------------|
| 1    | ZINC82039595 | 2/Ser_402,Thr_303          | -14.0216      | -43.505           |
| 2    | ZINC79037048 | 2/Ser_402,Thr_303          | -13.7116      | -12.706           |
| 3    | ZINC70632494 | Ser_402                    | -13.6374      | -12.402           |
| 4    | ZINC70632058 | Ser_402,Lys_486,Thr_353    | -13.6263      | -15.631           |
| 5    | ZINC77291968 | 2/Ser_402, Thr_353,Ser_304 | -13.4775      | -4.611            |



|    |              |  |          |         |
|----|--------------|--|----------|---------|
| 6  | ZINC68603627 | Ser_402, Thr_353,Ser_304<br>Ser_402, 2/          | -13.3565 | -24.017 |
| 7  | ZINC71784976 | Thr_353,Ser_304,<br>Ser_350,Thr_303,Lys_486      | -13.2932 | -14.609 |
| 8  | ZINC71784254 | Ser_350<br>Ser_304,Gln_349,                      | -13.2688 | -21.223 |
| 9  | ZINC83262599 | Ser_348<br>,Glu_489                              | -12.9355 | -24.523 |
| 10 | ZINC83240075 | Ser_402,Thr_303,Glu_489                          | -12.7459 | -13.654 |
| 11 | ZINC71782238 | 2/Ser_402, 2/Thr_353,<br>Ser_304,Ser_350,Ser_348 | -12.6694 | -16.840 |
| 12 | ZINC83330155 | 2/Ser_402, Thr_353,Ser_350                       | -12.6640 | -23.802 |
| 13 | ZINC77257146 | 2/Ser_402, Thr_303,<br>Lys_486,Val_400           | -12.5982 | -17.838 |
| 14 | ZINC72332550 | Thr_303,Ser_350                                  | -12.5801 | -13.232 |
| 15 | ZINC83324289 | 2/Ser_402, Thr_303,Lys_486,<br>Val_400,Ala_603   | -12.5482 | -25.679 |




FIGURE 4.11: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Glutamine-fructose-6-phosphate aminotransferase with ZINC 71782238

#### 4.3.3.4.12 Ribonuclease P Protein Component (rnpA)

Ribonuclease P protein is very old endonuclease that slices precursor tRNA and usually contains a catalytic RNA subunit (RPR) and one or more than one proteins (RPPs). It characterizes significant macromolecular complex and model system that is universally distributed in life. The gene that codes for the RNA subunit of ribonuclease P (RNase P) is necessary in all free-living organisms and plays a crucial role for their survival. This has been inferred from an evolutionary tree that the RNA subunit is a very old molecule and is an enzyme in nature. It is a cytoplasmic protein which is essential for the survival of bacteria, this can be a potential drug target after wetlab research.

TABLE 4.19: Compound name, MolDock Score and Interactive residues for Ribonuclease P protein component from MOE

| S.No | Ligand       | Interacting residues                    | Docking score | Energy (kcal/mol) |
|------|--------------|---|---------------|-------------------|
| 1    | ZINC71777128 | Lys_65_D,Arg_61_D,Arg_3_D               | -13.7073      | -25.890           |
| 2    | ZINC72145573 | Asp_68_D,Glu_2_D                        | -13.6183      | -17.224           |
| 3    | ZINC71609301 | Lys_65_D,Arg_58_D,Arg_3_D               | -13.5622      | -6.998            |
| 4    | ZINC77323423 | Lys_65_D,Arg_61_D,<br>Arg_3_D ,Lys_65_D | -13.4705      | -26.072           |
| 5    | ZINC71603173 | Asp_68_D, Glu_2_D                       | -13.1498      | -92.963           |
| 6    | ZINC70632388 | Glu_2_D, Lys_65_D                       | -13.0197      | -10.080           |
| 7    | ZINC73825281 | Glu_2_D                                 | -12.6744      | -13.724           |
| 8    | ZINC71372392 | Asp_68_D,Glu_2_D,Arg_69_D               | -12.6161      | -2.365            |
| 9    | ZINC83324781 | Arg_3_D, Asp_68_D                       | -12.5094      | -74.330           |
| 10   | ZINC71781167 | Lys_65_D,Arg_61_D,<br>Arg_3_D,Arg_58_D  | -12.5044      | -17.359           |
| 11   | ZINC68604796 | Asp_68_D,Glu_2_D                        | -12.2190      | -17.589           |
| 12   | ZINC72232764 | Asp_68_D                                | -12.0268      | -71.656           |
| 13   | ZINC70632508 | Lys_65_D,Glu_2_D                        | -11.8937      | -11.861           |
| 14   | ZINC71774240 | Arg_69_D,Glu_2_D,Ile_37_D               | -11.8699      | -8.960            |
| 15   | ZINC83312242 | Arg_3_D,Glu_2_D                         | -11.8425      | -28.299           |

Table 4.19 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.




FIGURE 4.12: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Ribonuclease P protein component with ZINC 71781167

#### 4.3.3.4.13 tRNA N6-adenosine Threonylcarbamoyl Transferase (tsaD)

Threonylcarbamoyladenine (t(6) A) is a customized nucleoside generally conserved in tRNAs in 3 kingdoms system of classification. The newly discovered genes for t(6) A synthesis, counting *tsaC* and *tsaD*, are necessary in prokaryotes without which prokaryotes cannot survive, but not necessary in yeast. *tsaC* and *tsaD* was identified as antibacterial targets even prior to their functions were recognized. It was verified that t(6) A is necessary in *Escherichia coli* for survival and a review of genome-wide essentiality studies illustrates that genes for t(6) A synthesis are crucial in the majority prokaryotes. It is essential protein for the survival of bacteria and drug prioritization also confirms that it could act as drug target. Table 4.20 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.

#### 4.3.3.4.14 Pseudouridine Synthase (MYPU\_2980)

Pseudouridine synthases belong to a group of enzymes that play a vital role in

TABLE 4.20: Compound name, MolDock Score and Interactive residues for tRNA N6-adenosine threonylcarbamoyltransferase from MOE

| S.No | Ligand       | Interacting residues                                     | Docking score | Energy (kcal/mol) |
|------|--------------|--|---------------|-------------------|
| 1    | ZINC70503687 | Asp_11_E,ZN-7:1  | -13.2577      | -74.138           |
| 2    | ZINC83312254 | Glu_12_E, ZN-7:1   | -12.0951      | -43.728           |
| 3    | ZINC72264470 | Asp_11_E   | -11.6701      | -41.364           |
| 4    | ZINC71610591 | ZN-7:1   | -11.5735      | -64.341           |
| 5    | ZINC72145573 | Asp_11_E   | -11.4157      | -39.292           |
| 6    | ZINC72266002 | No hit   | -11.0264      | -34.057           |
| 7    | ZINC72187410 | ZN-7:1   | -10.9755      | -298.362          |
| 8    | ZINC72267263 | Asp_298_E  | -10.9198      | -30.267           |
| 9    | ZINC71777792 | Asp_11_E   | -10.8572      | -3.093            |
| 10   | ZINC71372392 | Asp_11_E   | -10.6414      | -6.900            |
| 11   | ZINC83324781 | Glu_12_E,Asp_298_E,<br>His_115_E,His_139_E,<br>His_111_E | -10.6205      | -85.498           |
| 12   | ZINC74941352 | Glu_12_E   | -10.5529      | -42.480           |
| 13   | ZINC70632388 | No hit   | -10.5129      | -21.005           |
| 14   | ZINC78991044 | Glu_12_E   | -10.5048      | -52.835           |
| 15   | ZINC77323423 | ZN-7:1   | -10.4942      | -34.465           |




FIGURE 4.13: 3D Structure of Docking Analyses for most Druggable Protein Cavity of tRNA N6-adenosine threonylcarbamoyltransferase with ZINC 70503687

most abundant and phylogenetically conserved posttranscriptional modification of cellular RNAs, and appears to utilize both sequence and structural information to attain site specificity. Pseudouridine synthases catalyze an isomerization reaction of specific uridine residues contained by an RNA chain. Structure and Sequence

analyses have thus far demonstrated the existence of six synthase families that share a common core domain structure despite very low sequence identity.

TABLE 4.21: Compound name, MolDock Score and Interactive residues for Pseudouridine synthase from MOE

| S.No | Ligand       | Interactingresidues               | Docking score | Energy (kcal/mol) |
|------|--------------|-----------------------------------|---------------|-------------------|
| 1    | ZINC72360976 | Tyr_65_                           | -12.7240      | -16.166           |
| 2    | ZINC71385043 | Tyr_65_,His_234_,Arg_31_          | -12.1696      | -10.591           |
| 3    | ZINC78903210 | Tyr_65_                           | -12.1425      | -12.038           |
| 4    | ZINC83301304 | Tyr_65_,His_34_,Arg_31_, Tyr_63_  | -12.0788      | -16.704           |
| 5    | ZINC69533491 | Tyr_65_,His_30_                   | -11.7710      | -19.240           |
| 6    | ZINC83429827 | Tyr_65_,His_34_,Arg_31_, Asp_33-E | -11.7553      | -16.153           |
| 7    | ZINC72194195 | Tyr_65_,His_30_,Arg_32_, Arg_63_  | -11.7215      | -19.744           |
| 8    | ZINC78547526 | Arg_31_,His_34_                   | -11.7139      | -14.595           |
| 9    | ZINC71777205 | His_34_,Arg_31_,Gln_35_           | -11.5940      | -14.776           |
| 10   | ZINC75629415 | His_34_,Arg_32_,Tyr_65_           | -11.5008      | -16.669           |
| 11   | ZINC71780763 | Tyr_65_,Ile_36_                   | -11.4083      | -21.586           |
| 12   | ZINC71285802 | Tyr_65_,Arg_31_                   | -11.3990      | -9.802            |
| 13   | ZINC71780174 | Arg_31_,Arg_63-E,Tyr_65_          | -11.3527      | -14.881           |
| 14   | ZINC79102849 | Asp_33-E, His_30_,Tyr_65_         | -11.2342      | -31.298           |
| 15   | ZINC78547466 | Asp_33-E, Arg_31_,His_34_         | -11.2211      | -9.888            |

Synthases display exquisite specificity in pinpointing the site of pseudouridylation within their RNA substrates, and each enzyme achieves this by structural elaborations of the conserved catalytic domain. It is a cytoplasmic protein which is essential for the survival of bacteria, this can be potential drug target after the

wetlab research. Table 4.21 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.




FIGURE 4.14: 3D Structure of Docking Analyses for most Druggable Protein Cavity of Pseudouridine synthase with ZINC83301304

#### 4.3.3.4.15 Peptidase S24-like Protein (HMPREF 1604\_02797)

Peptidase S24-like protein is cytoplasmic protein its molecular function is DNA binding. Peptidase is an enzyme it enhance the rate of proteolysis mean breakdown proteins into little polypeptides or single amino acids. This is typically done by breaking the peptide bonds within proteins by hydrolysis, a reaction where water breaks bonds.

Peptidase helps in several biological functions which includes digestion of proteins, protein catabolism [1][2] and cell signalling. It is essential protein for the survival of bacteria and drug prioritization also confirm that it could act as drug target. Table 4.22 illustrates a set of 15 potential ligands according to their MolDock score and minimized energy value from the above mentioned ZINC library.

*Streptococcus gordonii*, is a commensal (mutual benefit for host and bacteria) non-pathogenic bacteria among the normal flora of human oral microbiome. The specie is considered to play a significant role in initializing the formation of dental plaque or biofilm on teeth. It produces a surface where other bacteria can adhere. These

dental plaques later cause dental cavities and other damages to teeth health. This bacterium can enter blood as a result of an injury or wound and then colonizes blood clotting agents such as platelet fibrin thrombi, and starts damaging endocardium and heart valves.




FIGURE 4.15: 3D Structure of Docking Analyses for most Druggable Protein Cavity Peptidase S24-like protein with ZINC83442116

Considering human as host, 15 of proteins (Glutamine-fructose-6-phosphate aminotransferase, UDP-3-O-acylglucosamine N-acyltransferase, Ribonuclease P protein component, tRNA N6-adenosine threonylcarbamoyltransferase, Pseudouridine synthase, Bifunctional protein, AMP nucleosidase, Probable DNA-directed RNA polymerase subunit delta, ATP-dependent DNA helicase, Peptidase S24-like protein, TetR family transcriptional regulator, Chromosomal replication initiator protein,

TABLE 4.22: Compound name, MolDock Score and Interactive residues for Peptidase S24-like protein from MOE

| S.No | Ligand       | Interacting residues                                 | Docking score | Energy (kcal/mol) |
|------|--------------|--|---------------|-------------------|
| 1    | ZINC71618323 | 2/Arg_30_B,Ser_86_B,2/Arg_144_B                      | -14.4376      | -17.082           |
| 2    | ZINC72145573 | Arg_30_B,Ser_86_B,Tyr_138_B                          | -13.9080      | -15.808           |
| 3    | ZINC77537571 | Tyr_138_B,Lys_110_B                                  | -13.8724      | -10.346           |
| 4    | ZINC82039595 | Arg_30_B, Lys_110_B                                  | -13.0064      | -17.612           |
| 5    | ZINC68732144 | Lys_110_B  | -12.9061      | -10.550           |
| 6    | ZINC72291787 | Lys_110_B,Phe_129_B                                  | -12.7718      | -30.866           |
| 7    | ZINC83442116 | 2/Tyr_138_B, 2/Arg_30_B,Thr_26_B,Phe_140_B, Thr_26_B | -12.6838      | -18.400           |
| 8    | ZINC83313306 | 2/Lys_110_B  | -12.5315      | -20.514           |
| 9    | ZINC74723614 | Lys_110_B  | -12.4334      | -19.849           |
| 10   | ZINC77257146 | Arg_156_B,Arg_127_B,Glu_137_B                        | -12.3925      | -19.032           |
| 11   | ZINC83312254 | Tyr_138_B, Phe_140_B, Arg_144_B, 2/Ser_86_B          | -12.3571      | -20.810           |
| 12   | ZINC80053835 | Lys_110_B, Tyr_138_B,Asp_141_B                       | -12.3067      | -0.842            |
| 13   | ZINC71766299 | 2/Lys_110_B  | -12.0701      | -11.298           |
| 14   | ZINC71771223 | 2/Lys_110_B  | -12.0502      | -11.006           |
| 15   | ZINC71783234 | Arg_30_B,Ser_86_B,2/Arg_144_B, Phe_140_B             | -12.0324      | -15.964           |

UDP-N- acetyl muramoyl-tripeptide–D-alanyl-D-alanine ligase, HTH-type transcriptional regulator, UDP-N-acetyl mu- ramoyl-L-alanyl-D- glutamate–2,6- di-aminopimelate ligase) were considered as essential and non-host homologs, and have been subjected to virtual screening using ZINC library. The selected ligand molecules indicated positive interactions and can be novel drugs target of *Streptococcus gordonii*.



# Chapter 5

## Conclusions and Recommendations

Several bacteria are present on human skin, in nose area and most commonly in mouth area and gut in normal condition, sometimes lives throughout the life of human being and does not cause any disease but when they get chance or interact with other bacteria can cause diseases such type of bacteria are known as opportunistic bacteria.

### 5.1 Conclusions

The streptococci are pathogenic in nature but have very low virulence. *Streptococcus gordonii*, are primarily involved in development of biofilms on tooth surfaces also known as dental plaque they are also involved in development of infectious endocarditis i.e. inflammation of inner lining of heart. As treatment of this disease is very expensive and different bacteria has shown resistance against various commonly used antibiotics it is now important to find the novel therapeutic targets and drugs to cure and treat this disease. By using bioinformatics approach, determine the core proteins of 11 strains of *Streptococcus gordonii* and exploitation of 3D structure information of these proteins give us prioritize putative drug

and vaccines targets. In this study 20 proteins are pathogenic essential, non-host homologous. Out of which 15 are cytoplasmic and their comprehensive structural evaluation between the host and the pathogen proteins propose that these proteins can act as a therapeutic drug. Considering human as host these are the 15 proteins (Glutamine–fructose-6-phosphate aminotransferase, UDP-3-O-acylglucosamine N-acyltransferase, Ribonuclease P protein component, tRNA N6-adenosine threonyl-carbamoyltransferase, Pseudouridine synthase, Bifunctional protein, AMP nucleosidase, Probable DNA-directed RNA polymerase subunit delta, ATP-dependent DNA helicase, Peptidase S24-like protein, TetR family transcriptional regulator, Chromosomal replication initiator protein, UDP-N-acetylmuramoyl-tripeptide–D-alanyl-D-alanine ligase, HTH-type transcriptional regulator, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate–2,6-diaminopimelate ligase) considered as essential , non-host homologs and shows best interaction with the ligands so act as drug targets.

## 5.2 Recommendations

Future perspective of this study is to validate all 15 proteins in wet lab as various drugs are determined in-silico and then validated by wet lab techniques are now a day's used as medicine.

# Bibliography

- [1]. Liao, C. Y., Su, K. J., Lin, C. H., Huang, S. F., Chin, H. K., Chang, C. W., & Yeh, Y. C. (2016). Plantar purpura as the initial presentation of viridians Streptococcal shock syndrome secondary to *Streptococcus gordonii* bacteremia. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2016(9463895), pp.5.
- [2]. Facklam, R. (2002). What happened to the streptococci: overview of taxonomic and nomenclature changes. *Clinical microbiology reviews*, 15(4), pp. 613-630.
- [3]. Doern, C. D., & Burnham, C. A. D. (2010). It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. *Journal of clinical microbiology*, 48(11), pp. 3829-3835.
- [4]. Ikeda, A., Nakajima, T., Konishi, T., Matsuzaki, K., Sugano, A., Fumikura, Y., & Jikuya, T. (2016). Infective endocarditis of an aorto-right atrial fistula caused by asymptomatic rupture of a sinus of Valsalva aneurysm: a case report. *Surgical case reports*, 2(1), pp. 1-4.
- [5]. Teixeira, P. G., Thompson, E., Wartman, S., & Woo, K. (2014). Infective endocarditis associated superior mesenteric artery pseudoaneurysm. *Annals of vascular surgery*, 28(6), pp. 1563-e1.
- [6]. Yombi, J., Belkhir, L., Jonckheere, S., Wilmes, D., Cornu, O., Vandercam, B., & Rodriguez-Villalobos, H. (2012). *Streptococcus gordonii* septic arthritis: two cases and review of literature. *BMC Infectious Diseases*, 12(1), pp. 1-5.

- [7]. Fenelon, C., Galbraith, J. G., Dalton, D. M., & Masterson, E. (2017). *Streptococcus gordonii*—a rare cause of prosthetic joint infection in a total hip replacement. *Journal of surgical case reports*, 2017(1), pp. 235.
- [8]. Collazos, J., Martínez, E., & Mayo, J. (1999). Spontaneous bacterial peritonitis caused by *Streptococcus gordonii*. *Journal of clinical gastroenterology*, 28(1), pp. 45-46.
- [9]. Cheung, C. Y., Cheng, N. H., Chau, K. F., & Li, C. S. (2011). *Streptococcus gordonii* peritonitis in a patient on CAPD. *Renal failure*, 33(2), pp. 242-243.
- [10]. <https://microbewiki.kenyon.edu/index.php/File:Streptococcusgordonii.jpg>
- [11]. Murdoch, D. R., Corey, G. R., Hoen, B., Miró, J. M., Fowler, V. G., Bayer, A. S., & Chambers, S. T. (2009). Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis—Prospective Cohort Study. *Archives of internal medicine*, 169(5), pp. 463-473.
- [12]. Vickerman, M. M., Minick, P. E., & Mather, N. M. (2001). Characterization of the *Streptococcus gordonii* chromosomal region immediately downstream of the glucosyltransferase gene. *Microbiology*, 147(11), pp. 3061-3070.
- [13]. Yajima, A., Y. Takahashi, and K. Konishi. 2005. Identification of platelet receptors for the *Streptococcus gordonii* DL1 sialic acid-binding adhesin. *Microbiol. Immunol.* 49, pp. 795-800.
- [14]. Gonzalez-Barca, E., Fernandez-Sevilla, A., Carratala, J., Granena, A., & Gudiol, F. (1996). Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. *European Journal of Clinical Microbiology and Infectious Diseases*, 15(4), pp. 291-296.
- [15]. Kern, W., Kurrle, E., & Schmeiser, T. (1990). Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. *Infection*, 18(3), pp. 138-145.

- [16]. Ofek, I., Hasty, D. L., & Sharon, N. (2003). Anti-adhesion therapy of bacterial diseases: prospects and problems. *FEMS Immunology & Medical Microbiology*, 38(3), pp. 181-191.
- [17]. Tilley, D., & Kerrigan, S. W. (2013). Platelet-Bacterial Interactions in the Pathogenesis of Infective Endocarditis—Part I: The Streptococcus. *Recent Advances in Infective Endocarditis*, pp. 13-33.
- [18]. Chong, C. E., Lim, B. S., Nathan, S., & Mohamed, R. (2006). In silico analysis of *Burkholderia pseudomallei* genome sequence for potential drug targets. *In silico biology*, 6(4), pp. 341-346.
- [19]. Dutta, A., Singh, S. K., Ghosh, P., Mukherjee, R., Mitter, S., & Bandyopadhyay, D. (2006). In silico identification of potential therapeutic targets in the human pathogen *Helicobacter pylori*. *In silico biology*, 6(1, 2), pp. 43-47.
- [20]. Sakharkar, K. R., Sakharkar, M. K., & Chow, V. T. (2004). A novel genomics approach for the identification of drug targets in pathogens, with special reference to *Pseudomonas aeruginosa*. *In silico biology*, 4(3), pp. 355-360.
- [21]. Barh, D., & Kumar, A. (2009). In silico identification of candidate drug and vaccine targets from various pathways in *Neisseria gonorrhoeae*. *In silico biology*, 9(4), pp. 225-231.
- [22]. Rathi, B., Sarangi, A. N., & Trivedi, N. (2009). Genome subtraction for novel target definition in *Salmonella typhi*. *Bioinformatics*, 4(4), 143.
- [23]. Aronov, A. M., Verlinde, C. L., Hol, W. G., & Gelb, M. H. (1998). Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. *Journal of medicinal chemistry*, 41(24), pp. 4790-4799.
- [24]. Singh, S., Malik, B. K., & Sharma, D. K. (2008). Molecular modeling and docking analysis of *Entamoeba histolytica* glyceraldehyde-3 phosphate dehydrogenase, a potential target enzyme for anti-protozoal drug development. *Chemical biology & drug design*, 71(6), pp. 554-562.

- [25]. Hassan, S. S., Tiwari, S., Guimarães, L. C., Jamal, S. B., Folador, E., Sharma, N. B., & Póvoa, F. D. (2014). Proteome scale comparative modeling for conserved drug and vaccine targets identification in *Corynebacterium pseudotuberculosis*. *BMC genomics*, 15(S7), pp. 3.
- [26]. Jamal, S. B., Hassan, S. S., Tiwari, S., Viana, M. V., Benevides, L. D. J., Ullah, A., & Silva, A. (2017). An integrative in-silico approach for therapeutic target identification in the human pathogen *Corynebacterium diphtheriae*. *PloS one*, 12(10), pp. e0186401.
- [27]. Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., & Urade, M. (2010). Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. *Journal of bone and mineral metabolism*, 28(4), pp. 365-383.
- [28]. Herzberg M C, Meyer M W. Effects of oral flora on platelets: possible consequences in cardiovascular disease. *J Periodontol*. 1996;67: pp.1138–1142.
- [29]. Salvà-Serra, F., Jakobsson, H. E., Thorell, K., Gonzales-Siles, L., Hallbäck, E. T., Jaén-Luchoro, D., & Bennisar, A. (2016). Draft genome sequence of *Streptococcus gordonii* type strain CCUG 33482T. *Genome Announcements*, 4(2), pp. 653-666.
- [30]. Telford, J. L., Barocchi, M. A., Margarit, I., Rappuoli, R., & Grandi, G. (2006). Pili in gram-positive pathogens. *Nature Reviews Microbiology*, 4(7), pp. 509-519.
- [31]. Kiliç, A. O., Tao, L., Zhang, Y., Lei, Y., Khammanivong, A., & Herzberg, M. C. (2004). Involvement of *Streptococcus gordonii* beta-glucoside metabolism systems in adhesion, biofilm formation, and in vivo gene expression. *Journal of bacteriology*, 186(13), pp. 4246-4253.

- [32]. Plummer, C., & Douglas, C. W. I. (2006). Relationship between the ability of oral streptococci to interact with platelet glycoprotein Iba and with the salivary low-molecular-weight mucin, MG2. *FEMS Immunology & Medical Microbiology*, 48(3), pp. 390-399.
- [33]. Marsh, P. D. (2003). Are dental diseases examples of ecological catastrophes?. *Microbiology*, 149(2), pp. 279-294.
- [34]. Mosailova, N., Truong, J., Dietrich, T., & Ashurst, J. (2019). *Streptococcus gordonii*: A Rare Cause of Infective Endocarditis. *Case Reports in Infectious Diseases*, 7127848, pp. 562-570.
- [35]. Njuguna, B., Gardner, A., Karwa, R., & Delahaye, F. (2017). Infective endocarditis in low-and middle-income countries. *Cardiology Clinics*, 35(1), pp. 153-163.
- [36]. Ambrosioni, J., Hernandez-Meneses, M., Téllez, A., Pericàs, J., Falces, C., Tolosana, J. M., & Moreno, A. (2017). The changing epidemiology of infective endocarditis in the twenty-first century. *Current infectious disease reports*, 19(5), pp. 21.
- [37]. Dadon, Z., Cohen, A., Szterenlicht, Y. M., Assous, M. V., Barzilay, Y., Raveh-Brawer, D., & Munter, G. (2017). Spondylodiskitis and endocarditis due to *Streptococcus gordonii*. *Annals of Clinical Microbiology and Antimicrobials*, 16(1), pp. 68.
- [38]. Li, X., Kolltveit, K. M., Tronstad, L., & Olsen, I. (2000). Systemic diseases caused by oral infection. *Clinical microbiology reviews*, 13(4), pp. 547-558.
- [39]. Tariq, M., Alam, M., Munir, G., Khan, M. A., & Smego Jr, R. A. (2004). Infective endocarditis: a five-year experience at a tertiary care hospital in Pakistan. *International journal of infectious diseases*, 8(3), pp. 163-170.
- [40]. Shahid, U., Sharif, H., Farooqi, J., Jamil, B., & Khan, E. (2018). Microbiological and clinical profile of infective endocarditis patients: an observational

- study experience from tertiary care center Karachi Pakistan. *Journal of cardiothoracic surgery*, 13(1), pp. 94.
- [41]. Netzer, R. O. M., Altwegg, S. C., Zollinger, E., Täuber, M., Carrel, T., & Seiler, C. (2002). Infective endocarditis: determinants of long term outcome. *Heart*, 88(1), pp. 61-66.
- [42]. Durante-Mangoni, E., Bradley, S., Selton-Suty, C., Tripodi, M. F., Barsic, B., Bouza, E., & Konečný, P. (2008). Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. *Archives of internal medicine*, 168(19), pp. 2095-2103.
- [43]. Carlos Guimaraes, L., Benevides de Jesus, L., Vinicius Canario Viana, M., Silva, A., Thiago Juca Ramos, R., de Castro Soares, S., & Azevedo, V. (2015). Inside the pan-genome-methods and software overview. *Current genomics*, 16(4), pp. 245-252.
- [44]. Marsh, P. D. (2003). Are dental diseases examples of ecological catastrophes?. *Microbiology*, 149(2), pp. 279-294.
- [45]. Hinse, D., Vollmer, T., Rückert, C., Blom, J., Kalinowski, J., Knabbe, C., & Dreier, J. (2011). Complete genome and comparative analysis of *Streptococcus gallolyticus* subsp. *gallolyticus*, an emerging pathogen of infective endocarditis. *BMC genomics*, 12(1), pp. 400.
- [46]. Blom, J., Kreis, J., Spänig, S., Juhre, T., Bertelli, C., Ernst, C., & Goesmann, A. (2016). EDGAR 2.0: an enhanced software platform for comparative gene content analyses. *Nucleic acids research*, 44(W1), pp. W22-W28.
- [47]. Li, L., Stoeckert, C. J., & Roos, D. S. (2003). OrthoMCL: identification of ortholog groups for eukaryotic genomes. *Genome research*, 13(9), pp. 2178-2189.
- [48]. Emmerth, M., Goebel, W., Miller, S. I., & Hueck, C. J. (1999). Genomic Subtraction Identifies *Salmonella typhimurium* Prophages, F-Related Plasmid



- Sequences, and a Novel Fimbrial Operon, *stf*, Which Are Absent in *Salmonella typhi*. *Journal of bacteriology*, 181(18), pp. 5652-5661.
- [49]. Zhang, Z., & Ren, Q. (2015). Why are essential genes essential?-The essentiality of *Saccharomyces* genes. *Microbial cell*, 2(8), pp. 280.
- [50]. Uddin, R., Siraj, B., Rashid, M., Khan, A., Ahsan Halim, S., & Al-Harrasi, A. (2020). Genome Subtraction and Comparison for the Identification of Novel Drug Targets against *Mycobacterium avium* subsp. *hominissuis*. *Pathogens*, 9(5), pp. 368.
- [51]. Wadood, A., Jamal, S. B., Riaz, M., & Mir, A. (2014). Computational analysis of benzofuran-2-carboxylic acids as potent Pim-1 kinase inhibitors. *Pharmaceutical biology*, 52(9), pp. 1170-1178.
- [52]. Trost, E., Blom, J., de Castro Soares, S., Huang, I. H., Al-Dilaimi, A., Schröder, J., & Azevedo, V. (2012). Pangenomic study of *Corynebacterium diphtheriae* that provides insights into the genomic diversity of pathogenic isolates from cases of classical diphtheria, endocarditis, and pneumonia. *Journal of bacteriology*, 194(12), pp. 3199-3215.
- [53]. Luo, H., Lin, Y., Gao, F., Zhang, C. T., & Zhang, R. (2014). DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. *Nucleic acids research*, 42(D1), pp. D574-D580.
- [54]. Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R. K., & Crowther, G. J. (2008). Genomic-scale prioritization of drug targets: the TDR Targets database. *Nature reviews Drug discovery*, 7(11), pp. 900-907.
- [55]. Brennan, R. G., & Matthews, B. W. (1989). The helix-turn-helix DNA binding motif. *Journal of Biological Chemistry*, 264(4), pp. 1903-1906.

- 
- [56]. Gay, N. J., Tybulewicz, V. L., & Walker, J. E. (1986). Insertion of transposon Tn7 into the Escherichia coli glm S transcriptional terminator. *Biochemical Journal*, 234(1), pp. 111-117.
- [57]. Luscombe, N. M., Austin, S. E., Berman, H. M., & Thornton, J. M. (2000). An overview of the structures of protein-DNA complexes. *Genome biology*, 1(1), pp. 10-30.
- [58]. Gay NJ, Tybulewicz VL, Walker JE. Insertion of transposon Tn7 into the Escherichia coli glmS transcriptional terminator. *Biochem J.* 1986;234(1), pp.111-117. doi:10.1042/bj2340111